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                                           INTRODUCTION 
 
The sense of smell is a multidimensional event (1). Olfaction acts as a 
pleasurable stimulus and has been shown to affect quality of life. It plays a major role 
in modifying dietary behaviour and also acts as an important surveillance system in 
safety and prevention (2).  During the process of mastication of food, flavour released 
is transmitted to the olfactory cleft via the nasopharynx. This pathway of retronasal 
olfaction is essentially involved for appreciating flavour of food. The perception of 
olfactory stimuli is emotionally linked. Odours relating  to memories of the past, are 
capable of evoking strong emotions (3).  
Olfactory impairment has historically been overlooked as a public health 
problem. Olfactory dysfunction exposes patients to potentially life-threatening events 
such as increased risk of cooking accidents, inability to detect fires and gas leaks and 
ingestion of toxic or spoiled substances. These are hazards and collectively pose a 
significant public health risk (2,4).  Several studies indicate that  frequent exposure to 
different odours can lead to improvement of olfactory function. The stimulation of 
olfaction is based on the ability of the olfactory system to regenerate. An olfactory 
training programme requires exposure to each odorant for 10 seconds for a duration of 
4 to 6 months. The odours usually suitable  for the training include lemon, eucalyptus,  
rose and cloves, which belong to odour categories fruity, ﬂoral, resinous, and aromatic 
(3). 
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There are various physiological and pathological conditions that affect the 
sensation   of olfaction. In the present study, the chemosensation of patients with 
primary head and neck malignancies is assessed at different intervals of radiotherapy.  
Head and neck malignancies involving the nasopharynx, oropharynx, oral 
cavity, and sinonasal region are often treated with radiation therapy. In patients 
undergoing conformal radiotherapy, the radiation fields include the olfactory cleft 
region. Such patients usually complain of deteriorating chemosensory function and 
quality of life during the course of treatment. Following therapy, there is reportedly 
gradual improvement in the olfactory function as the olfactory system regenerates. In 
some patients, the recovery is delayed and the deterioration in function seems to 
persist. However there is contradicting literature on this subject. Hence we decided to 
do a study to make a subjective and objective assessment of the olfactory function, 
mucociliary clearance and quality of life after initiation of radiotherapy in head and 
neck cancer patients.  
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AIMS & OBJECTIVES 
 
Aim: 
To assess the effect of radiotherapy on olfaction in patients with head and neck       
malignancies treated with radiotherapy (RT). 
Objectives: 
1) To compare olfaction before, mid RT, end of RT and 3 months after 
radiotherapy 
2) To evaluate the effect of radiotherapy on mucociliary clearance time using 
saccharin test before radiotherapy, mid RT, end of RT and 3 months after 
radiotherapy 
3)   To compare the quality of life using Appetite, Hunger and Sensory 
Perception (AHSP) Questionnaire before radiotherapy, mid RT,  end of RT and 
3 months after radiotherapy 
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DEVELOPMENT OF NASAL CAVITY AND OLFACTORY REGION 
There are a number of mesenchymal processes surrounding the primitive 
stomatodeum from which the nose develops. The frontonasal process arises between 
the central aspect of the forebrain and the epithelial roof of mouth. A highly 
specialised ectodermal tissue called olfactory placode develops during the 5th week of 
intrauterine life on each side of the ventral surface of the frontonasal processes which 
separate it into median and lateral nasal processes. The olfactory placode forms a 
depression called the olfactory pit (5,6). The stratified placodal base of the 
invagination forms the olfactory epithelium. The lateral walls around the invaginating 
pits form the surface ectodermal covering of the nasal cavities. The placodal cells of 
the olfactory epithelium differentiate into neurosensory cells within the thickness of 
the epithelium and eventually give origin to olfactory nerve fibres.  At the end of third 
month, the mesenchyme between the sensory epithelium and the bulb gives rise to the 
lamina cribrosa of the ethmoid bone which is eventually organized around the 
olfactory nerve networks and separates them into a number of bundles. The lamina 
ossifies here to form the cribriform plate of the ethmoid through which the nerves pass 
to enter the olfactory bulbs. At about 5 months, the axons of the superficial cells cross 
the epithelium and the mesenchyme and reach the olfactory area of the cerebral 
hemisphere. The axons then connect with the specialized structures of the central 
nervous system corresponding to the olfactory system. The olfactory bulb elongates, 
and eventually the extension of the ventricular cavity into it becomes obliterated. Cells 
in the bulb around which the olfactory nerve fibres terminate and synapse, give origin 
to secondary olfactory fibres which grow centrally and form the olfactory tract. The 
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olfactory tract terminates in the region of the piriform. In lower mammals, the 
olfactory nerve is distributed to the vomero nasal organ  found in the lower part of the 
nasal septum (7). On the lateral wall of the nose a series of elevations appear within 
the nasal cavity within the 6th week of intrauterine life which ultimately forms the 
turbinates (5,6). 
 
 
 
Fig 1 : Development of nasal cavity and olfactory region 
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ANATOMY OF NOSE  
EXTERNAL FRAMEWORK OF NOSE  
The external nose is a pyramidal shaped structure made of cartilages and bones. 
It is a delicate organ which serves the cosmetic function and act as the gateway of 
respiratory tract.  
Nasal bones 
The nasal bone is wedge-shaped and its surface is grooved by neurovascular 
bundles (5,7). The 2 nasal bones articulate with each other  in the midline forming the 
bridge of the nose. Superiorly the nasal bone is attached with the frontal bone, 
inferiorly with the upper lateral cartilage and laterally with the frontal process of the 
maxilla at the nasolacrimal suture.  The nasal bone ossifies from a membranous centre 
which lies over the anterior part of cartilaginous nasal capsule.  
Cartilages of the external nose and columella 
The nasal cartilages are hyalinised structures which prevent collapse of the 
vestibule on inspiration. There are 2 triangular shaped upper lateral cartilages which 
articulate superiorly with the nasal bones and are overlapped by them, by the adjacent 
frontal processes of the maxillae and inferiorly by the lower lateral held by the ﬁbrous 
tissue. The junction between the upper and lower cartilages is known as the limen 
nasi, which is the site of intercartilaginous incisions. The lower lateral cartilage has 
medial and lateral crura which form the dome of the tip. Columella is formed by the 
medial crura of the 2 lower lateral cartilages in the midline, anterior to the 
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quadrilateral cartilage (7). The minor sesamoid cartilages are present between the 
upper and lower nasal cartilages. Nasal bones and cartilages are lined by periosteum 
and perichondrium (5). The skin and soft tissues over the dorsum of nose and along 
the nasal bridge is thin and loosely adherent while it is thicker and more adherent over 
the tip (7). 
Blood supply 
Branches of the facial artery supply the alar region while the dorsum and lateral 
walls of the external nose are supplied by the dorsal branch of the ophthalmic artery 
and the infraorbital branch of the maxillary artery (7,8). 
Nerve supply 
The skin of the external nose receives its sensory supply from the two upper 
divisions of the trigeminal nerve; ophthalmic and maxillary. The anterior ethmoidal 
nerve  traverses the dorsum of the nose to supply the tip. The infraorbital nerve 
supplies the lateral nasal walls, columella, and vestibule (7). 
 
VESTIBULE  
The external nose has a dilated pathway called the vestibule which leads into 
the nasal cavities. It is demarcated by the limen nasi, at the superior margin of the 
lower lateral cartilage (5).  The vestibule is lined by skin containing hair follicles, 
sebaceous glands and sweat glands.  
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NASAL CAVITY 
The nasal cavity is divided into 2 halves by the nasal septum. Each nasal cavity 
extends anteriorly from the external nares to the choanae posteriorly, which is 
continuous with the nasopharynx. The nasal cavity is narrower anteriorly and widens 
as it extends posteriorly (7). The surface area of the nasal cavity is about 160 cm2, or 
96 m2 if the microvilli are included (9). 
Vertically, it extends from the palate to the cribriform plate, being broader at its 
base and narrows to the olfactory cleft superiorly. Each half has a ﬂoor, a roof, a 
lateral wall and a medial (septal) wall. The floor is formed by the palatine process of 
maxilla and the horizontal process of the palatine bone. A depression in the mucous 
membrane above the incisive canals 12mm posterior to the anterior end of the ﬂoor  
transmits the branches of nasopalatine nerve, the greater palatine artery and a short 
mucosal canal (Stenson’s organ) (7). The roof is formed by the cribriform plate of 
ethmoid and this area lined by the olfactory epithelium is considered as the olfactory 
area. It is the dangerous area of nasal cavity as it is through the cribriform plate  which 
has perforations that the olfactory nerve fibres pass directly into the anterior cranial 
fossa and infection can spread intracranially following surgery or trauma or with 
associated CSF rhinorrhoea (5,10).  There are about 20 perforations called foramina 
on each side of the nose. This is the only site in the body where the central nervous 
system is in direct contact with the outer surface (7).  
The olfactory neuroepithelium is distributed in 3 major areas: the superior 
septum, the superior aspect of the superior turbinate, and to a slightly lesser degree the 
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superior aspect of the middle turbinate. These structures define the olfactory cleft (11). 
The olfactory cleft is a paired oriﬁce located in the medial and upper regions of the 
nasal cavity. This cleft is limited by the middle turbinate laterally, the nasal septum 
medially, the cribriform plate and the superior turbinate superiorly, the inferior margin 
of the middle turbinate inferiorly, and the anterior face of sphenoid sinus posteriorly 
(12). 
 
Fig 2 : Olfactory area 
NASAL SEPTUM 
The nasal septum is made up of bony and cartilaginous framework. The 
cartilaginous framework of the nasal septum consists of  a quadrilateral cartilage with 
contribution from the lower and upper lateral cartilages. The membranous columella is 
the part of the nasal septum formed between the medial crus of the lower lateral 
cartilage and the quadrangular cartilage.  
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The perpendicular plate of the ethmoid bone forms the superior and anterior 
bony septum, extends above to attach to the cribriform plate and crista galli. The 
vomer forms the  posterior portion of the  septum and articulates with the rostrum of 
the sphenoid. The inferior border of the vomer articulates with the nasal crest of 
maxilla and the palatine crest. The anterior border articulates with the perpendicular 
plate above and the quadrilateral cartilage inferiorly. The posterior edge of  vomer 
remains free. The surface area of the septum measures between 30 and 35cm2 in 
adults (7). 
 
LATERAL WALL OF NOSE  
 It is an irregular surface formed by scrolls of bones which is the site of 
drainage of sinus secretions (5,7). 
Inferior turbinate 
This structure is composed of the inferior concha which is a separate bone 
having an irregular surface, lined by respiratory epithelium  and its subepithelium 
containing cavernous venous plexus with large sinusoids under autonomic control 
which provides the major contribution to nasal resistance. It also articulates with the 
ethmoid, palatine and lacrimal bones, completing the medial wall of the nasolacrimal 
duct. The turbinate possesses an impressive submucosal cavernous plexus. The 
turbinate is covered by a large number of goblet cells which decrease in density 
towards the posterior end (7). 
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Inferior meatus   
The inferior meatus lies lateral to the inferior turbinate and extends along the 
entire length of the nasal cavity. The opening of the nasolacrimal duct  which is at the 
anterior third of the inferior meatus is guarded by a mucous membrane called 
Hasner’s valve (13,14). 
Middle  turbinate 
 The middle turbinate forms the medial wall of the middle meatus and is 
attached superiorly to the cribriform plate. At the middle third of the middle turbinate, 
it forms the basal lamella which separates the anterior and posterior ethmoidal air cells 
and inserts in to the lateral wall of nose. The posterior end of the turbinate forms a 
boundary of the sphenopalatine foramen (9). 
Middle meatus 
The middle meatus is one of the most important areas of the nose that lies 
between the middle turbinate and lateral wall of nose.  The anterior group of sinuses 
that is the frontal, maxillary and anterior ethmoidal sinuses drain into the middle 
meatus. A thin piece of bone known as the uncinate process is a wing or boomerang 
shaped piece of bone forming the first layer or lamella of the middle meatus.  It is 
related anteriorly to the posterior edge of the lacrimal bone, and inferiorly to the 
superior edge of the inferior turbinate. Superior attachment of the uncinate process is 
highly variable, may be attached to the lamina papyracea, or the roof of the ethmoidal 
sinus, or sometimes to the middle turbinate. The maxillary sinus ostium is bounded by 
the mucous membrane of the maxillary sinus.  The membranous area lying anterior to 
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the uncinate process is the anterior fontanelle while membranous area posterior to the 
uncinate is posterior fontanelle. Accessory ostia are found most frequently in the 
posterior fontanelle which occurs as a result of  recurrent chronic sinusitis in 25% 
cases while it may be present naturally also (7,13). 
Superior turbinate 
The superior turbinate is attached to the skull base and forms boundary to the 
olfactory cleft (11).  
Superior meatus 
This meatus is again deﬁned by its relationship to the superior turbinate. The 
posterior ethmoidal cells open into this region (11).  
Sphenoethmoidal recess 
The ostium of the sphenoid sinus opens into the sphenoethmoidal recess lying 
medial to the superior turbinate. 
 
PARANASAL SINUSES  
The paranasal sinuses are air-filled cavities within the skull lined by a thin 
layer of respiratory mucosa of the nose from the nasal cavity. They are divided into an 
anterior and a posterior group.  
The anterior group including frontal, anterior ethmoidal and maxillary sinuses 
drain into the middle meatus of the nose. In the posterior group , the posterior 
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ethmoidal cells drain into the superior meatus and the sphenoid sinus drains  into the 
sphenoethmoidal recess (9,10). 
Maxillary sinus  
The maxillary sinus (antrum) is a paired pyramidal structure formed by the 
malar process, lower part of the lateral wall of the nose and the floor of the orbit. The 
roots of the canine, molars and premolars produce different eminences over the 
maxilla. The maxillary ostium is located at the junction of anterosuperior and 
posteroinferior aspect of infundibulum, hence drainage is dependent on ciliary action 
and not gravity. The average adult size of the maxillary sinus is 35 mm high, 30 mm 
anteroposteriorly and 25 mm wide with a volume of 15 ml (9,10,13). 
Frontal sinus    
These are a pair of funnel shaped structures situated within the frontal bone 
above the supraorbital margin and root of the nose with their ostia directed 
downwards. They are asymmetric and divided by a vertical bony septum called 
interfrontal septum (7,9,10). 
Ethmoidal sinuses 
The ethmoid sinus labyrinth is a cavity made up of honey comb network of 
small cells that vary in number and size. It is related laterally to the medial wall of the 
orbit (lamina papyraceae) and medially to the nasal cavity. Superiorly, it is attached to 
the  anterior cranial fossa, near the midline, on either side of the cribriform plate 
(fovea ethmoidalis). The anterior ethmoidal air cells are small and numerous and drain 
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into the middle meatus. The posterior ethmoidal air cells are fewer in number and 
drain into the superior meatus (6,8).  
Sphenoid sinus 
The sphenoid sinuses lie within the body of the sphenoid bone, divided by a 
vertical septum. They are rudimentary at birth and true growth of the sphenoid sinus 
only occurs at puberty. Laterally, the sinus is related to the internal carotid artery, the 
optic nerve and the cavernous sinuses which contain the IIIrd, IVth, ophthalmic and 
maxillary divisions of Vth and Vlth cranial nerves. The olfactory apparatus and the 
frontal lobes lie superiorly and the pituitary fossa lies posteriorly (10). 
HISTOLOGY 
The nasal septum is lined by the mucoperichondrium and mucoperiosteum. The 
nasal mucosa is predominantly respiratory epithelium with olfactory epithelium lining 
the roof of nose adjacent to the cribriform plate. Respiratory epithelium is composed 
of ciliated and nonciliated pseudostratiﬁed columnar cells, basal pluripotent stem cells 
and goblet cells. Each cell bears 300–400 microvilli. There are a number of  ﬁnger-
like cytoplasmic extensions called  cilia which serve to increase the surface area and  
prevent drying of nasal mucosa. The cilia beat in a specific direction such that the 
secretions are directed posteriorly into the nasopharynx and can be swallowed (5). The 
cilia consists of multi – structural classical axonema of nine peripheral doublet and 
two central single microtubules (9+2 pattern). Of the paired microtubules peripheral 
pair (A and B) connects to the next doublet and to the central microtubule with hexin 
links. The A microtubule contains 2 arms, an outer and inner dynein arm, composed 
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of ATPase which extends to the B microtubule. This is responsible for the ciliary 
movement.  Several seromucinous glands present in the submucosa are involved  in 
mucus production. Within the sinuses are numerous goblet cells. In newborns, the 
septal mucosal surface is 450mm2 with 17–18 glands/ mm2, compared with the adult 
septum of 1700mm2 and 8.5 glands/mm2.  
 
Fig 3 : Cross section of an Axoneme 
 The olfactory epithelium lines the cribriform plate onto the corresponding part 
of the septum medially. Olfactory region is a small area of 2.5 mm2on each side 
containing approximately 50 million primary sensory receptor cells. This region 
consists of olfactory bipolar receptor cells, supporting cells with microvilli and basal 
stem cells conferring on olfactory epithelium the capacity for regeneration. Each 
receptor cell has approximately 17 cilia. Dynein arms are absent between the 
microtubules. The sensory endings have a characteristic knob-like vesicular structure 
from which olfactory ﬁbres join the axonal bundle. There is a sharp transition zone 
between the olfactory and respiratory epithelium though the relative area of each 
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varies with age and reﬂects the decrease in olfactory acuity. Secretion for the olfactory 
epithelium is provided by Bowman’s glands (5,7). 
 
 
Fig 4 : Types of olfactory cells 
 
PHYSIOLOGY OF NOSE  
The primary function of the nose is respiration and olfaction. The nose acts as 
an air conditioning unit of inspired air and performs three functions: humidiﬁcation, 
heat transfer and ﬁltration. The sense of smell is essential in our daily existence and its 
deterioration is the earliest signs of several diseases. It is also required for ability to 
taste and determines the flavour of food items (10). 
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GENERAL PHYSIOLOGY OF NOSE  
Different functions of the nose are:  
Airway for respiration 
Filters suspended particulate matter from inspired air  
Air –conditions (humidifies and regulates temperature) the inspired air 
 Bactericidal to organisms in inspired air 
Transports mucus posteriorly to lubricate the pharynx 
Collects the moisture from expired air to prevent excessive loss 
Provides the voice with a pleasing resonant quality 
Integral part of the olfactory system. 
 
OLFACTION 
Olfaction is one of the distal senses from ancient times which initiates and 
modiﬁes behaviour in many creatures. Though much emphasis is given to cosmetic 
and visual appearance of an individual, yet much money is spent modifying body 
odour.  It is a source of livelihood for several workers such as cooks, homemakers, 
fire fighters, plumbers, wine merchants, perfumers, cosmetic retailers, chemical plant 
workers (10).   
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Olfaction requires odorant molecules in air flow to reach olfactory mucosa in 
the roof of the nose. These receptor molecules need high water and lipid solubility. 
Diffusion of odorant molecules through the mucous on the mucous membrane excite 
the bipolar olfactory receptor neurons (ORNs). The solute in mucus is presented to the 
sensory mucosa. Olfactory mucosa and pathway easily fatigues and regenerates 
quickly at the same which facilitates man’s ability to differentiate several smells (15).  
Olfactory tests usually look at the threshold and suprathreshold (7). 
Suprathreshold tests include odour identification and odour discrimination which are 
related to the cognitive function. While sniffing there is a rapid change in airflow 
velocity which allows the trigeminal nerve to alert the olfactory nerve fibres that an 
odorant molecule is coming. It is the universally performed manoeuvre when 
presented with an olfactory stimulus although the best stimulus is prolonged 
inspiration (10). 
 
Olfactory area 
The olfactory surface area is the region involving the superior third of the 
superior turbinate corresponding part of the nasal septum and the cribriform plate 
200–400mm2 with a density of receptor cells of approximately 5104 receptor 
cells/mm2. The receptor cells derived from the basal cells  bear modiﬁed cilia, which 
increase the surface area and regenerate every month. 
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Fig 5 : Olfactory cleft of nose 
Stimulus 
Absorption of  molecules by the mucosa from the air occurs  which influences 
the spectrum of chemicals reaching the olfactory cleft. Highly absorbable chemicals 
may have minimal or no odour as they never reach the olfactory cleft. Odours react 
with the lipid bilayer of the receptor cells at speciﬁc sites, which causes potassium and 
chloride  to ﬂow out and thus depolarize the cells and a slow action potential is 
recorded on the electroolfactogram (EOG) (7). 
Receptors 
Receptors are first order neurons derived from ectoderm. Glial-type cells that 
ensheath olfactory neurons support axonal growth of both olfactory and non-olfactory 
neurons. Each receptor cell expresses a single odorant receptor gene. There are more 
than 1,000 different types of receptors which are responsive  to a wide range of 
stimuli. Receptors are confined to non-overlapping strip like zones. Olfaction is 
 20 
 
mediated by G-protein coupled receptors in the cells which interact with a speciﬁc 
adenylcyclase within the neuroepithelium.  
Threshold 
Olfactory responses show both variations in thresholds and adaptation. 
Threshold depends on the chemical nature of stimuli and the level of inhibitory 
activity from the higher centres. The threshold of perception is lower than 
identiﬁcation that is a smell is sensed before it is recognized and it increases with 
exposure. Thresholds are affected by changes in nasal mucus and its pH,  age and 
hormones. 
Adaptation 
Adaptation of olfactory responses is a peripheral and central phenomenon. 
Cross adaptations are present between odours at high concentration (7,16). 
Pathways 
From the olfactory neuroepithelium, bipolar receptor cell projects from the 
nasal cavity into the brain without an intervening synapse. Odour perception involves 
the interaction of odorant molecules with highly specialised and specific receptor 
sites. Receptor cells are connected to the olfactory bulb by nonmyelinated nerve ﬁbres 
which synapse on olfactory glomeruli. Conduction time between the receptor cells and 
the glomerulus is 50ms. The impulse is transmitted from the glomeruli by an all or 
none response into mitral or tufted cells whose axons transport the signal through the 
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lateral olfactory tract. Normal life span of olfactory neurons ranges from 30 to 90 days 
(17). 
The olfactory pathway can be broadly divided into a peripheral system which             
receives the odorant stimuli and a central pathway that processes the stimulus so              
generated.  
 
Fig 6 : Peripheral olfactory pathway 
 
Higher centres 
The olfactory bulbs lie on the ventral aspect of the frontal lobes. The olfactory 
nerves synapse on mitral cells whose axons project directly to the olfactory cortex. 
The olfactory tract connects the olfactory bulb with the cerebral hemispheres. Axons 
of mitral cells pass directly back to the olfactory cortex on the ipsilateral side that 
receives direct sensory input without an interposed thalamic connection  
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Fig 7 : Central olfactory connections 
 
Most of the olfactory cortex is of a primitive 3-layered type, located on the 
base of the frontal lobe and medial aspect of the temporal lobe overlying the anterior 
perforated substance through which the striate arteries enter the interior of the brain. 
On the temporal lobe the olfactory cortex covers the rostral portion of the 
parahippocampal gyrus including a medial bulge known as the uncus or uncinate 
gyrus. From the olfactory cortex, olfactory information is relayed via the mediodorsal 
nucleus of the thalamus to the insular and orbitofrontal cortex. The insular cortex 
within the Sylvian fissure, also receives taste input from the medial part of VPM and 
is believed to be the site where olfactory and taste information is integrated to produce 
the sensation that can be termed flavour. Inhibition comes from feedback from high 
cortical centres (7,8,15). 
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Trigeminal input  
Trigeminal nerve perceives upto 30 % of odours, but at high concentrations 
irritation occurs and can detect substances such as butyl acetate. Irritation contributes 
to the nature of smell. 
Theories of olfaction   
 The Steric Theory of Odour– stated air borne chemical molecules are 
smelled when they fit into certain complementary receptor sites on the 
olfactory nervous system. This "lock and key" approach was an 
extension from enzyme kinetics. 
 Vibrational theory – Postulated that there is a difference in vibrational 
frequency for every perceived smell. Odorant molecules that produce 
the same vibrational frequency produce the same smell 
 Luca Turin's theory of smell - reduced to its most basic nature is that the 
receptors in the nose respond to the different fundamental vibrations of a 
molecule and that produces the sensation of smell. There are most likely 
a number of different types of receptors responding to different ranges 
of vibrations. 
EFFECT OF OLFACTION ON  
a) Eating   
Olfaction helps two aspects of eating: the recognition of food types and the 
initiation of digestion. Initiation of digestion is mediated via the lateral and 
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ventromedial hypothalamus, causes salivation and increases output of gastric acid and 
enzymes (7). Flavour perception is closely related to olfaction. Flavours released 
during mastication reach the olfactory cleft via nasopharynx (3). 
b)  Sexual behaviour  
Pheromones are chemicals released by one member of a species and received by 
another member resulting in a specific action or developmental process. These were 
initially described in animals and insects. Several anatomic and behavioural studies 
support the possibility of human communication through odorants. Three types of 
pheromones have been described: releaser pheromones; primer pheromones; and 
imprinting pheromones.  
FACTORS AFFECTING OLFACTION  
(1) Age - Younger persons have thousands glomeruli which decrease in number 
with age and becomes nearly absent in the elderly after the age of 80 years 
(10). 
(2)  Gender – In general, many studies have consistently shown that women have 
a better olfactory ability than men both in threshold and identification. 
(3) Hormonal -  Menstrual cycle influences women’s olfaction threshold levels, 
being best at ovulation and reduced during menstruation (8). 
(4)  Neurodegenerative conditions – Decline in olfaction is seen in Alzheimer’s 
disease, Parkinson’s  and cognitive degeneration. 
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(5) Genetic variability -  Wide range of  variability in olfactory performance  may 
reflect different expression patterns of sets of  olfactory receptor genes, central 
processing effects, or genetic variability in the olfactory receptor (OR) genes  
(6)  Smoking – Current smoking was linked to olfactory dysfunction 
(7) Sinonasal diseases (18) 
 
DISORDERS OF SMELL   
Olfactory disorders are classified according to standard schemata. It is 
important to differentiate between a patient’s chemosensory complaint and the 
findings of objective testing, which are not always in congruence. 
Anosmia- refers to an inability to detect qualitative olfactory sensations (i.e. absence 
of smell function). 
Partial anosmia- ability to perceive some, but not all odours 
Hyposmia /microsmia- refers to decreased perception of odours.  
Hyperosmia–  increased sensitivity to common odours.  
Dysosmia - (sometimes termed cacosmia /parosmia) is distorted or perverted smell 
perception to odour stimulation. 
Phantosmia - is a dysosmic sensation perceived in the absence of an odour stimulus 
Also known as olfactory hallucination  
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Olfactory agnosia- refers to an inability to recognize an odour sensation, even though 
olfactory processing, language and general intellectual functions are essentially intact 
Heterosmia – a condition where all odours smell the same 
Presbyosmia – a decline in smell sense with age  
Osmophobia – a dislike or fear of certain smells (11). 
 
MUCOCILIARY CLEARANCE (MCC) 
Respiratory mucosa runs in continuity from the nose to the paranasal sinuses. 
Goblet cells and cilia are less numerous in general but more frequent near the ostia 
and the blood supply is less well developed with no cavernous plexuses, which give 
the sinus mucosa a pale colour. Since the nerve supply is less well developed, the 
sinus mucosa is able to give only a basic vasomotor response and increase mucus 
production with parasympathetic stimulation. 
Nasal secretions 
Nasal secretions contain mucus and water. Mucus glands produce glycoproteins while 
water and ions are produced by the serous glands and from transudation from the 
capillary network. There are several mixed glands in the submucosa which are 
arranged around ducts. Serous cells contain discrete electron dense granules producing  
neutral glycoproteins, enzymes such as lysozymes and lactoferrin as well as 
immunoglobulins of the IgA2 subclass. Goblet cells are more numerous in maxillary 
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sinus than other sinuses. The microbes and particulate matter if any gets entrapped in 
the secretions and are transported out. 
Drainage 
Mucociliary clearance in the maxillary sinus is spiral or stellate and towards the 
natural ostium. The secretions from the maxillary sinus start in a star shape from the 
floor of the maxillary sinus along its wall and opens into the ostium in the lateral wall 
of nose from where it is actively transported through the ethmoidal infundibulum 
posterior to the uncinate onto the medial surface of inferior turbinate and towards the 
nasopharynx.   
 
Fig 8 : Drainage of Paranasal Sinuses  
 
Drainage of the frontal and sphenoid sinuses is downwards and is aided by 
gravity, the blood supply is better developed in the frontal sinuses and the ostium is 
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relatively large in the sphenoid sinus. Messerklinger  described the transport of the 
mucous in the frontal sinus. 
Mucus from the sinuses joins that ﬂowing on the lateral nasal wall, with most 
mucus going through the middle meatus towards the nasopharynx (5). Mucus blanket 
consists of a superficial viscous  mucus layer and a deeper aqueous serous layer, 
floating on the top of cilia which are constantly beating to carry it like a “conveyer 
belt” towards the nasopharynx  (16). Secretions passing below the eustachian tube 
orifice is called infratubal stream. Secretions from the superior meatus and 
sphenoethmoidal  recess pass superior to the tubal orifice and is called as supratubal 
flow. 
Ciliary action 
 Between temperature of  320 and 400C  ciliary beat frequency is 7 - 16Hz  and 
remains constant.   
 Ciliary beat consists of a rapid propulsive stroke and a slow recovery phase.  
 Propulsive ( Rapid ) phase -  Initiation of ciliary beat occurs, the cilium is straight 
and the tip points into the viscous layer of the mucus layer (5,19). 
 Recovery (Slow ) stage -  the cilium is bent over in the aqueous layer in a 
tangential direction and returns to steady state position to initiate the next beat 
cycle.  
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Fig 9 : Conveyor belt mechanism 
Energy is produced by conversion of ATP to ADP by the ATPase of the dynein arms 
and the reaction is dependent of magnesium ions. The mucus blanket is thus propelled 
backwards by metachronous movement of cilia so that  mucus ﬂows from the front of 
the nose posteriorly (13). Mucociliary transport occurs at the rate of 1cm/min, 
although normal range may have wide variations. (11) 
FACTORS AFFECTING CILIARY ACTION 
 Active and passive tobacco smoke exposure 
 Gastroesophageal reflux 
 Narrowed nasal passages 
 Nasal septal deviation 
 Turbinate malformations 
 Nasal tumours 
 Nasal polyps 
 Foreign bodies 
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 Ciliary defects from beta blockers, viruses, dry environment, sulfur dioxide and 
genetic defects  
 Drying stops the cilia 
 Temperature > 1010 C and < 450C  
 pH > 6.4  and <8.5.  
 Age : Ciliary function may deteriorate with age. There is significant increase in 
the occurrence of microtubular defects, including disarrangement of 
microtubules and the presence of extra microtubules or single microtubules, 
with aging (20). 
 Oxygen tension – Oxygen tension is reduced in the sinuses if the ostium is 
blocked. Ciliary motion is compromised if the blood supply is inadequate and 
leads to reduced motility and stasis of secretions.  
TESTS FOR MUCOCILIARY CLEARANCE  
Various tests that can be performed to evaluate mucociliary clearance : 
Saccharin test 
Rhinoscintigraphy / Nuclear testing 
Mucus flow rate with 99m Tc-labelled resin particle 
Mucociliary transit time with colouring substances 
Nasal Nitric Oxide  
Mucus flow rate with radiopaque Teflon disks 
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Saccharin test  
This test is done to assess physiological mucociliary clearance and is 
considered the standard technique. Saccharin test was described by Anderson et al in 
1974 (21). Test is performed with patient in sitting position. A 0.5mm particle  of 
saccharin is placed 1 cm behind the anterior end of the inferior turbinate and the time 
is noted. Patient is advised to not to sniff or sneeze and to breathe normally through 
the nose and swallow saliva every 30 seconds (22,23). Patient is told to refrain from 
eating or drinking during the test. When a sweet sensation was perceived the nasal 
mucociliary transport time is recorded in minutes. Saccharin test is easy to perform, 
inexpensive and can be done in an outpatient setting (23,24). If the sweetness was not 
perceived after 30 min, the procedure can be abandoned and the saccharin particle 
placed on the tongue to check ability for taste (25).  
Alternatively,  a colouring agent (methylene blue, indigo blue, charcoal) may 
be added to the saccharine particle which serves as a visual control and its presence 
can be visualised in the pharynx. While the normal mucociliary transport time is about 
10 minutes, a mucociliary transport time of up to 30 minutes is still considered 
normal. Prolonged time interval of more than 30 minutes is considered abnormal.  
Reasonable cooperation of the patient is required as the patient must report the 
sweet taste. Prohibition of sniffing, sneezing, and blowing the nose during the test 
limits the use of the test in children. The saccharine has to be placed on respiratory 
(ciliated) epithelium. On combining this procedure with nasal endoscopy, the coloured 
particles can be visualised to evaluate the transport pattern with the perception of the 
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sweet  taste (11).Saccharin test is a useful screening technique. It is inexpensive, non-
invasive, readily available, results are reproducible and simple to perform (17).  
 
 
Table 1 : Nasal mucociliary clearance time 
 
Rhinoscintigraphy / Nuclear testing   
The measurement of mucociliary transport velocity by rhinoscintigraphy with 
99m Tc- labelled macroaggregated albumin (99mTc-MAA) is a reliable measure of 
MCC. A small amount of radiolabelled Tc99m albumin colloid particles is placed on 
the nasal septum or on the inferior turbinate and the migration is followed with a γ-
camera. Normally, most of the radioactivity would have disappeared within 30 
minutes. The percentage of radioactivity that remains in the nasal cavity can be 
calculated, and in sagittal views, the migration of the spot can be measured. 
Rhinoscintigraphy test is more reliable than the saccharine test and is not affected by 
sneezing unlike the saccharine test, but it requires expensive equipment and can only 
be done in specialized centres (8,21).  
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Mucus flow rate with 99m Tc-labelled resin particle   
A radiotracer such as 99mTc is used placed on the upper surface of the inferior 
turbinate, 0.5-0.8 cm behind the anterior end. Serial Polaroid pictures are taken at 
regular intervals using a gamma camera till the resin particles reach the nasopharynx. 
This also aids in the calculation of the distance travelled by the particles from their 
original position and the time at the beginning of the exposure and the exposure time 
must also be recorded (8). 
Mucociliary transit time with colouring substances-  
This is a simple, non invasive and inexpensive technique of assessment in 
which a  droplet of a dye such as indigo carmine is placed in the anterior part of the 
nasal cavity. Periodic inspection of the pharyngeal wall is done and the time taken 
between  placement of the dye and its appearance in the pharyngeal wall is noted (8). 
Nasal Nitric Oxide 
Nasal nitric oxide test is a noninvasive  and easy screening test for the 
diagnosis of primary ciliary dyskinesia. This test requires the cooperation of the 
patient in breath holding for stable plateau measurements which limits its use in 
children (8).  
Mucus flow rate with radiopaque Teflon disks   
Mucociliary transport is determined by imaging of radiopaque teflon disks 
introduced into the nose using a Fluroscope image intensifier (17). 
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TESTS OF OLFACTION  
In the assessment of a patient with chemosensory dysfunction, three major 
steps are encountered: (a) obtaining a detailed clinical history; (b) testing olfactory 
function quantitatively; and (c) physically examining the head and neck. The cause of 
olfactory loss is elicited in history, events such as head trauma, upper respiratory tract 
infections, toxic exposures, or iatrogenic interventions. Specific history concerning the 
nature, timing of onset, severity, progression, duration and pattern of fluctuation is to 
be noted. Sudden olfactory loss suggests head trauma, infection, ischemia, or a 
psychogenic condition. Gradual loss can reflect the development of degenerative 
processes or progressive obstructive lesions within (11).  
There are  several tests designed to test olfaction from three-item Pocket Smell 
Test to the 40-item University of Pennsylvania Smell Identification Test (UPSIT). 
Olfactory function can be assessed using numerous psychophysical tests and some 
subjective scales, such as visual analogue scales (VAS) and the six-item Hyposmia 
Rating Scale. The UPSIT is commercially known as the Smell Identification Test and 
is the most widely used and highly reliable olfactory test, having been administered to 
an estimated 400,000 patients. The test can be self administered in 10–15 minutes by 
the patient while waiting in the outpatient department.  The scoring can be done 
subsequently in less than a minute by any nonmedical personnel. There are several 
versions and the test in available in regional languages American, British, Chinese, 
French, Italian, German, Spanish and Japanese versions. It consists of four booklets 
containing ten microencapsulated (‘scratch and sniff ’) odorants apiece (7,11,26). 
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Test results relate to a percentile score of a patient’s performance as compared to age- 
and sex-matched controls.  
 
Olfactory function can be interpreted as : 
normosmia 
mild microsmia 
moderate microsmia 
severe microsmia 
anosmia 
probable malingering.  
 
Olfactory event-related potentials ( OREP )   
            The recording of olfactory event-related potentials (OREP) has been done in 
specialized medical centres to assess the integrity of the olfactory system which is a 
complex, specialized and expensive equipment capable of delivering a odorant pulse 
into the nose with continuous ﬂow of  warmed and humidiﬁed air (7).  Although, 
OERPs are sensitive and can detect malingering, it lacks the ability to localize any 
anomaly in the olfactory pathway (9). 
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Electroencephalography (EEG ) 
 Brain electroencephalography (EEG) elicits synchronized brain activity 
recorded from overall EEG activity during brief presentations of odorants (7). This 
technique involves the placement of surface electrodes under endoscopic guidance on 
the surface of the olfactory mucosa which gathers reflected summated generator 
potentials mainly from olfactory receptor neurons (11). 
Sniffin’ sticks test  
 It is a standardized, re-usable, validated test based on odour filled felt-tip pens. 
It  consists of three parts: odour threshold, odour discrimination, and odour 
identification. The threshold task reflects the function of the olfactory periphery, while 
the suprathreshold tests (discrimination and identification) are more related to 
cognitive function (3,27). 
 
Connecticut Chemosensory Clinical Research Centre test ( CCCRC )  
 Connecticut Chemosensory Clinical Research Centre (CCCRC) test is 
administered using  n – butyl alcohol, a sweet smelling agent as odorant for threshold. 
It is an inexpensive, portable and can easily be administered test. Butanol is a widely 
used odorant as it is a water soluble,  readily available,  neutral odorant with low 
toxicity. CCCRC test is a 2 component test were olfactory threshold and odour 
identification are assessed.  
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Threshold testing 
 Threshold testing is assessed using serial dilutions of 60 ml 4% n- butanol in 
polythene squeeze bottles in such a way that the spout of the bottle is placed in a 
specified nostril and squeezed and sniff simultaneously. Test is initiated with the 
lowest concentration paired with a blank bottle. If an incorrect response was given, 
next higher concentration paired with a blank bottle was given until four correct 
responses were elicited in a row.  
 To accurately assess olfaction unilaterally, the naris contralateral to the tested 
side should be occluded without distorting the patent nasal valve region. Occlusion 
not only prevents air from entering the olfactory region from the naris (orthonasal 
stimulation), but prevents active movement of odour-laden air into the occluded side 
from the rear of the nasopharynx (retronasal stimulation). Microfoam tape cut to ﬁt the 
contralateral naris borders may also be used. The patient is instructed to sniff the 
stimulus normally and to exhale through the mouth (28,29). 
Odour identification  
A test kit with 10 plastic containers of 180 ml capacity with sachets of odorants 
is presented unilaterally while the opposite side is occluded. Commonly used day to 
day items were used, namely, Cinnamon, asafoetida, coffee, tea, pepper, cloves and 
Johnson’s baby powder. 
Another 3 chemical items also used ( Eucalyptus, Rose, Lemon ).  From a 20 
item list containing the 10 test items along with 10 distractors, patient attempts to 
recognise the right odour.  Test is done unilaterally while occluding the opposite side. 
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If a patient is unable to identify, the response was corrected by the examiner and the 
missed items were given a second trial in random order. 
 
Composite Score   
The olfactory threshold and identification was combined to get composite score. A 
composite score of 6 and above accounts for 90 % of the normal individuals (16). 
>  6 – Normosmia 
           5 – 6 – Mild hyposmia 
           4 – 5 – Moderate hyposmia 
           2 – 4 – Severe hyposmia 
<  2– Anosmia (16) 
Olfactory dysfuntion  
There are 3 types of olfactory dysfunction 
Conductive loss- Obstruction of nasal passages. Eg : chronic inflammation,               
polyposis 
 Sensorineural loss – Damage to olfactory neuroeithelium Eg :viral, air borne 
toxins, radiation 
 Central olfactory neural loss – CNS damage. Eg : tumours, neurodegenerative 
disorders (11,30) 
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RADIOTHERAPY   
Radiation therapy refers to treatment of cancer using ionising radiations which 
when employed releases energy in a localised area that is within a target cell and 
breaks the chemical bonds in the nucleus. Free radical such as H and OH and 
oxidising agents react with genes and breaks them. 
Effects of radiation – Irradiation is most effective when the G2 – M mitotic phase of a 
cell cycle is targeted. It causes early cell death, prevents or delays cell division, 
permanently damages the cell which is then passed on to daughter cell. 
Radiotherapy (RT) is a common treatment modality for patients with head and 
neck malignancies as a potentially curable primary modality or as adjuvant RT. A 
large number of early stage tumours have a high response rate to this treatment. The 
radiation treatment of the patients with head and neck cancer is considered one of the 
most challenging treatments in radiotherapy. This is because the volume that should 
be irradiated has a convex shape encompassing the spinal cord, which is the most 
critical organ at risk (OAR) at this site. Also the anatomy of the body itself, where the 
volume that should be irradiated is located, ranging from the thick bony structures at 
the face, thin contour of the upper neck and to the thick surface of the supraclavicular 
areas poses a challenge in delivering the adequate dose. The maximal dose tolerated 
by the spinal cord is 45 Gy - 50 Gy. The presence of the other OAR like the oral 
cavity and the parotid glands, complicate the treatment further (31). In most cases, 
addition of  radiotherapy to surgery improves 5-year survival when compared to RT 
alone or surgery alone. Preoperative radiation may obscure the initial extent of 
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disease, surgery resection may not control the microscopic extensions of the tumor , 
increases the infection rate and the risk of post- operative wound complications. 
Postoperative radiation therapy is started 4 to 6 weeks after surgery.  
Post op radiotherapy dose  indicated – 
Negative margin   – 60 Gy in 30 #  
Positive / close margin  - 66 Gy in 33 # 
Gross residual disease  – 70 Gy in 35 # 
Three-dimensional conformal radiotherapy (3D-CRT) which has  become 
recently available has the potential for tailoring the isodose surfaces to the shape of 
the tumour (i.e., the planning target volume [PTV]) in all three dimensions (31).  
The classical approach in the treatment of the planning target volume (PTV) is 
to irradiate it up to the maximal allowable dose with two lateral photon fields (usually 
of 6 MV) and then to reduce the fields from the dorsal side in order to spare the spinal 
cord. In this way the target radiation dose to the tumour is not compromised, with a 
low maintained “volume-weighted” dose burden to normal tissues. The irradiation 
doses used in radiation  for tumour control in H&N cancer are usually  60 – 70 Gy 
which is much more than the tolerance of the radiation-sensitive structures such as the 
spinal cord, optic nerves, or salivary glands. The cause of such disturbances can be 
due to direct radiation-induced damage to taste cells and buds, salivary glands, and 
taste nerve fibres. The xerostomia secondary to salivary gland damage can influence 
food transport, protection from bacterial invasion, and salivary proteins potentially 
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involved in taste transduction and can aid in the promotion of opportunistic oral 
infections, for example, oral candidiasis (20). Permanent injury to the salivary glands 
occur even at subtherapeutic radiation doses in the range of 22–24Gy in 2-Gy 
fractions causing fibrosis, hyposecretion, and xerostomia. Xerostomia may predispose 
to infections, caries and disturbed speech and swallowing.   
Radiotherapy leads to transient hypogeusia (especially for bitter and salty 
tastes) or even ageusia, which is most pronounced approx. 2 months after irradiation. 
The taste disturbance can persist for 1 to 2 years after radiotherapy.  Dental 
prophylaxis if not addressed may lead to osteoradionecrosis of mandible.  
Parotid gland salivary flow deteriorates after a cumulative dose of 30–50 Gy 
given with conventional fractionation. This can be prevented in by using a conformal 
parotid-sparing RT technique. 
 
CONFORMAL THERAPY   
This is the radiotherapy treatment modality that creates a high dose volume that 
is shaped to closely “ conform” to the desired target volumes while minimizing the 
dose to critical normal tissues. 
 
Advantages of Conformal Radiotherapy   
1) Three dimensional contouring on CT images can be drawn so that target volumes 
can be obtained.  
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2) Multiple beam directions are used to crossfire on the targets.  
3) Individual beams are shaped or intensity modulated to create a dose distribution 
that conforms to the target volume and desired dose levels.  
4) Use of image guidance, accurate patient setup, immobilization and management of 
motion to ensure accurate delivery of the planned dose distributions to the patient. 
 
Types of Conformal Radiation  
 Techniques aiming to employ geometric ﬁeld shaping alone( 3D-CRT)   
 Techniques to modulate the intensity of ﬂuence across the geometrically- 
shaped ﬁeld (IMRT)  
 
3-D CRT  
Treatment based on 3D anatomic information such that radiation dose 
distribution is maximised to the target volume that the tumour receives while  
minimising treatment of   adjacent normal tissues.  This is achieved by designing 
beam shapes and beam orientations to improve dose conformation. 
 
IMRT  
It is an advanced form of 3D CRT.  IMRT refers to a radiation therapy 
technique using computer-aided optimization to modulate the intensity of incoming 
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radiation beams to a higher degree of special agreement so that specified dosimetric 
volume is obtained in targeted areas. It is more advanced than 3D CRT and can alter 
the margins between planning target volume and target volume.  
 
Advantages of IMRT  
Improved precision and accuracy using 9 + beams and thousands of segments 
Lower rate of complication 
Lower cost of patient care following treatment  
Large fields and boosts can be integrated in single treatment plan  
Radiobiologic advantage. 
 
Limitations of IMRT  
Variation in positioning  
Intrafraction motion  
Changes of physical and radiobiologic characteristic of tumour and normal tissue  
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VOLUMES  
Two volumes should be defined prior to treatment planning 
Gross tumour volume (GTV) – all known gross disease which is visible / palpable 
including its extension and location. This includes primary tumour and metastatic 
lymphadenopathy 
Clinical target volume (CTV) -  It is the volume surrounding the gross tumour 
volume including the areas of potential microscopic spread 
 Planning target volume - is a geometrical concept which provides a margin around 
the clinical tumour volume to allow variations may be intra-fractional or inter-
fractional due to number of factors like – movement of tissues/patient, variations in 
size & shape of tissues, variations in beam characteristics. It considers the net effect of 
the geometrical variations to ensure that the prescribed dose is actually absorbed in the 
CTV.  
The boost volume consists of areas at greatest risk for recurrence, such as close 
or positive resection margins,  regions of perineural invasion, extracapsular spread, 
advanced T stage and multiple cervical metastasis. 
 
RADIOTHERAPY INDUCED PATHOPHYSIOLOGICAL CHANGES  
In primary head and neck tumours such as oral cavity, oropharyngeal, 
nasopharyngeal and brain tumours radiation with substantial doses to the olfactory 
epithelium is inevitable. Several studies have shown impairment of olfactory function 
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as a side effect of radiotherapy (9). In tumours arising from the olfactory cleft, 
olfactory groove meningiomas, frontal lobe gliomas and suprasellar ridge 
meningiomas arising from the dura of the cribriform plate, due to the olfactory nerve’s 
close location to the roof and medial wall of the orbit, as well as the optic nerves and 
tracts, lesions may affect vision also. Olfactory tumours may extend into the frontal 
lobes resulting in symptoms of dementia.  
Mass lesions need not be in the olfactory tracts to cause smell impairment. In 
radiotherapy for nasopharyngeal cancer, radiation exposure is local and can affect 
only the receptor cells and nerve endings in the olfactory region of the upper nasal 
vault. Suprathreshold olfactory discrimination and identiﬁcation involve higher brain 
centers, which are spared from radiation delivered to the nasopharynx. 
 Deterioration of olfaction following  radiation may occur due to  changes in 
the nasal mucosa and mucositis which alter  the perception of olfactory stimuli (32).  
At higher doses of 60 Gy, alterations of the cell cycle and depletion of basal cells of 
the olfactory epithelium occurs. A decreased turnover of olfactory neurons may occur 
due to the arrest of mitosis in the basal cell layer which is essential for differentiation 
of mature olfactory nerve cells. However, olfactory neurons are believed to have a 
turnover time of approximately 30 days, and hence recovery of olfactory dysfunction 
is expected sooner. Irradiation also causes damage to the Bowman’s glands in the 
olfactory epithelium which dissolve odorants and present them to bipolar receptor 
cells. Mucosal oedema secondary to irradiation can block the access of odorants to the 
olfactory area, causing a conductive type hyposmia. Patients may not necessarily 
perceive nasal airway obstruction, but this could restrict air flow to the roof of the 
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nose. Alternatively, nasal mucositis  leads to changes in airflow and the mucociliary 
clearance which may have drastic effects on olfactory function and prolonged sinusitis 
in irradiated persons (33–35).  
Finally, olfactory dysfunction may have resulted from temporary neuronal 
demyelinization which can occur in some patients receiving brain irradiation  known 
as the "early" delayed reaction to radiation therapy.  This reaction generally improves 
within six to 36 weeks, corresponding to the turnover time of myelin. Histologic 
sections of human adult olfactory mucosa reveal tissue degeneration and cell depletion 
as well as replacement of the olfactory mucosa by nasal respiratory mucosa.  It is 
possible that even this moderate amount of radiation was enough to cause significant 
damage to the mucosa, such that it did not fully recover even six months after 
treatment(35).  
RT to the head and neck region in frail elderly patients can result in serious 
consequences because important tissues are often included in the field of irradiation. 
Dental problems, xerostomia, gustatory dysfunction and mucositis eventually 
contribute to poor nutritional status and cancer cachexia and consequently lead to low 
quality of life in patients.  
Patients undergoing radiation experience disturbance in taste and smell causing 
loss of appetite. Taste aversions can be long lasting and can produce generalized 
anorexia and cachexia (11). Radiation-induced dysguesia can occur as a result of 
changes such as  depletion of neural progenitor cells, damage to central neural 
pathways and sensory mechanism along with depletion of sensory cells by scatter or 
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exit radiation dose (36).  Parotid gland salivary flow is severely impaired in 
conventional fractionation with a  cumulative dose of 30–50Gy. More recently, using 
conformal parotid-sparing RT technique moderate to severe xerostomia may be 
prevented in most patients (29, 32).  
Good QOL is a state of physical, psychological and social well-being, in which 
the individual is able to perform everyday activities and reports satisfaction with daily 
function. While overall QOL following radiotherapy has been assessed, little is known 
about the quality of oral function and taste and olfaction. Patients experience reduced 
taste (ageusia) or altered taste (dysgeusia) while undergoing radiation therapy or 
chemoradiation, which can signiﬁcantly impact on the quality of life. They develop 
oral mucositis, cachexia, signiﬁcant weight loss due to decreased appetite and nutrient 
absorption(37).  
The AHSP questionnaire aims to assess taste, smell, hunger and appetite for 
such patients prior to commencement of treatment and after treatment to study the 
impact on the patients’ quality of life during the course of their therapy. This 
questionnaire is based on assessing the nutritional status of a patient not only on 
enquiries made regarding the quality and quantity of food intake but also based on 
subjective analysis of patients perception of hunger and appetite besides taste and 
olfaction (38). 
 Two potential pathways were described by Croy et al regarding impairment of 
quality of life by olfactory dysfunction. Reduced food appetite and enjoyment , 
worries about personal hygiene and reduced social interaction predisposes patients to 
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depression. Further more, olfactory loss affects the brain’s functioning and, especially, 
emotional control due to reduced input from the olfactory bulb via amygdala into the 
limbic circuit (39). 
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METHODOLOGY 
A study on the “Effects Of Radiotherapy On Olfaction And Nasal Function 
In Head And Neck Cancer Patients” was proposed, and it was put forward to the 
Institutional Research Board. After obtaining the approval from the ethics committee, 
IRB dated -08/08/2016, Min no. : 10209, the study was initiated from September 2016 
Study Design:  
This is an observational prospective cohort study. 
Study Population: 
Patients who presented to the ENT OPD diagnosed with primary malignancy of 
head and neck and planned for radiotherapy fulfilling the inclusion and exclusion 
criteria were recruited in the study. 
Inclusion Criteria:  
1.  Patients above 16 years, diagnosed with malignancy of head and neck planned for 
conformal radiotherapy 
2. Radiotherapy field includes olfactory cleft region 
3. Normal olfaction before radiotherapy 
4. No prior radiotherapy or surgery of the olfactory region 
Exclusion Criteria: 
1. Patients below 16 years 
 50 
 
2. Malignancy involving the olfactory cleft and anterior skull base 
3. Nasal cavity tumours 
Study Period:  
This prospective study was conducted between September 2016 and August 2017. 
Statistics  
Sample Size Calculation 
The sample size was calculated using nMaster 2.0 software.  
              To study the parameter change between baseline and post RT (3 months), the 
sample size calculation is done here. 
Single Mean - Paired t-test 
 
OT MCT 
Pre-test mean 6.4 9.4 
Post-test mean 5.5 30.6 
Standard deviation in Pre-
test 0.4 0.4 
Standard deviation in Post-
test 1.1 1.1 
Effect size 1.2 28.26667 
Power (%) % 80 80 
Alpha Error 5 5 
1 or 2 sided 2 2 
Required sample size 7 2 
 
The calculated minimum sample size for this study is 7. Anticipating a few drop outs 
and   lost to follow ups we decided to conduct the study with three times the sample 
size, 21 subjects. 
References: Veyseller et al (2014) and Gupta et al (2006). 
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Prospective Study Recruitment: 
This study is a hospital based prospective observational study on patients with 
head and neck malignancies who were planned for conformal radiotherapy for whom 
the olfactory cleft region is included in the radiation portal with normal baseline 
olfactory function. 
Patients who presented to the ENT OPD diagnosed with primary head and neck 
cancer after discussion in the MDT planned for radiation therapy were included for 
the study.  A baseline olfaction was assessed for all patients and only patients having a 
normal olfactory threshold were recruited in the study.  The CCCRC (Connecticut 
Chemosensory Clinical Research Center ) test consisting of Odour threshold and 
Odour Identification was performed. 
Simultaneously, mucociliary clearance time using saccharin test and 
assessment of quality of life using a AHSP questionnaire were done prior to initiation 
of radiotherapy. These patients were followed up mid RT, immediate post RT and at 3 
months after radiotherapy and the tests were repeated. 
Connecticut Chemosensory Clinical Research Center Test (CCCRC) test was 
used in which, the threshold of subjects for butanol was elicited by means of squeeze-
bottles using the method of ascending limits. After occluding one nostril, testing was 
started with the lowest concentration. The participant was presented with a bottle with 
the test concentration and a blank bottle with water and had to decide which smelled 
stronger. Four correct choices in a row led to cessation of testing and the 
concentration at which this occurred was taken as the olfactory threshold. Similarly, 
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the test was repeated in the opposite side. Odour identification was performed by 
means of eight bottles containing different odorants with a multiple choice from a list 
of 16 items identical for all odorants. Seven bottles were with items that exclusively 
stimulate sense of smell and one with an item that appeal to common chemical sense 
by trigeminal stimulation. The score for the test comprised of the number of olfactory 
items out of seven correctly identified. A composite score was calculated with the 
average of olfactory threshold score and odour identification scores.  
Saccharin test is a simple test to assess nasal mucociliary clearance where a 
small 1mm particle of saccharin was placed approximately 1 cm behind the anterior 
end of the inferior turbinate. The patient was instructed not to sniff, sneeze, or cough 
during the test and to report a taste as soon as it was noted. In the presence of normal 
mucociliary action, the saccharin sweeps backwards to the nasopharynx and a sweet 
taste is perceived. Failure of sweetness to be detected within 20 minutes signifies 
delayed mucociliary clearance. 
 
Quality of life assessment was done using Appetite, Hunger and Sensory 
perception questionnaire which is a validated, 29-item, multidomain appetite 
assessment tool that was scored with a 5-point (A to E) Likert-type scale with verbally 
labelled categories.  
Questions are divided in to 5 sections:  
1) Present odour perception (3 items, score range 3 – 15) 
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2) Present odour perception compared to the past (3 items, score range 3 – 15) 
3) Present taste perception (8 items, score range 8 – 40) 
4) Appetite (6 items, score range 6 – 30) 
5) Daily feeling of hunger (9 items, score range 9 – 45) 
 
The score for each domain was calculated as the sum of scores on the individual 
items. The total AHSP score is the sum of scores on all the domains. Possible scores 
ranged from 29 (worst) to 145 (best) (38,40). 
All the study patients were planned for RT simulation with immobilisation and 
the reference CT isocenters marked on the immobilisation device. After that the 
planning CT scan was done as per the institutional protocol with the radio opaque 
marker in the CT isocenters. The CT images were transferred to the contouring work 
station in the Radiotherapy treatment planning system (RT-TPS). The tumour volume, 
organs at risk and the olfactory cleft region were marked by the Radiation Oncologist 
in the CT images and the images were transferred for treatment for inverse treatment 
planning after prescribing the doses to the organs at risk and Tumor volumes. 
After proper optimization the best plan was used for the treatment delivery 
after the quality assurance tests. The maximum dose, Mean dose and other dose 
volume effects  to the olfactory cleft region will be analysed with the change in the 
olfactory and nasal function. 
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Statistical Analysis 
The descriptive analysis was used for the data description at baseline. Pre post 
testing was performed using Paired samples t test. p value <0.05 was considered as 
statistically significant. 
 
Fig 10 : Flow chart showing study methodology 
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RESULTS 
A total of 21 patients who fulfilled the inclusion and exclusion criteria as per the study 
protocol were recruited in the study. Three patients were lost to follow up as 1 patient 
had disease progression on follow up and dropped out and two other patients were 
unwilling to continue in the study. 
  
 
 
    
 
  
 
 
 
 
 
 
Fig 11 : Flowchart of recruitment of study cases 
  
 
Agreed to participate 
 
Inclusion / exclusion criteria  applied 
Recruited     n= 21 
 
Surgery +  RT     n=  4
  
Radiation n=2 Chemoradiation n=15 
Mid RT       n= 21  
 
Drop out   n=3 
End of RT   n= 18 
 
3 months follow up n = 13 
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Age Distribution  
The age of the patients recruited in the study ranged from 16 – 75 years ( mean – 
42.62, Standard deviation – 17.40 ). Most of the patients were within the 16 – 30 year 
and 46 – 60 year age groups. There was no significant difference in the distribution in 
different age groups.                            
 
 
Fig 12 : Age distribution (n = 21 ) 
 
Gender distribution 
16 ( 76.20% ) of our patients were male while only 5  (23.80% ) were female.  
Mean – 42.62 
StdDev – 17.40 
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Fig 13 : Gender distribution ( n = 21 ) 
 
Comorbidities 
 A majority of our patients (81% ) did not have any comorbidities. 2 patients were 
diabetic and 2 patients were hypertensive on regular medication. 
 
Fig 14 : Comorbidities (n = 21 ) 
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Comorbidities
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Diagnosis 
In the study as the inclusion criteria required olfactory area to be included in the 
radiation field, most of the cases were malignancies involving nasopharynx (61.9%) 
followed by oropharynx (19%), oral cavity (9.5%) and sinonasal region ( 9.5% ). 
 
Fig 15 : Diagnosis / primary site of disease ( n = 21 ) 
 
Treatment 
Considering the different primary sites, treatment modality of these patients varied 
from neoadjuvant chemotherapy followed by radiotherapy in 15 patients ( 71.5 % ), 
surgery followed by adjuvant radiotherapy in 4 patients ( 19% ) and radiotherapy 
alone in 2 patients ( 9.5% ).  
 59 
 
 
Fig 16 : Treatment modality  
Histology 
The study group showed a wide range of histological variants with poorly 
differentiated carcinoma being the most common. 
 
Fig 17 : Histological types in the study 
 
5
1
10
1
2
2
0 5 10 15
Undifferentiated
nasopharyngeal ca
Clear cell mucoepidermoid ca
Poorly differentiated ca
Heamangiopericytoma
Moderately differentiated SCC
Well differentiated SCC
Histology
No. of patients
 60 
 
Olfactory threshold   
The olfactory threshold of both sides nasal cavities were analysed separately adhering 
to strict inclusion criteria of normal olfactory threshold to start with. Hence only 39 of 
the 42 nasal cavities (21 patients) were taken for analysis. A diagrammatic 
representation of the olfactory threshold at different timepoints show a deteriorating 
trend in the threshold as the radiation exposure increases. 
 
 
Fig 18 : Performance based on olfactory threshold scores 
 
On further analysis the decrease in the olfactory threshold was significant at each time 
period, including the 3 month follow up  as compared to the baseline as shown in the 
test of significance. Both right and left sides were analysed separately. 
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Olfactory 
threshold 
( Right ) 
Median 
 ( IQR ) 
p value 
( overall ) 
                          Paired 
 p value 
 
Pre RT                                            
Mid RT           
End of 
RT 
3 months 
post RT 
 
     6 
 6 
     4 
 
     6 
 
 
 
0.001 
 
Pre RT – Mid RT                                                            
 
Pre RT – End of 
RT                                  
 
Pre RT – 3 
month follow up 
 
0.004
 
             0.002 
 
 
             0.026 
Table 2a :  Olfactory threshold scores ( Right side ) during radiotherapy –                 
Test of significance 
 
Olfactory 
threshold 
( Left ) 
Median 
 ( IQR ) 
p value 
( overall ) 
                          Paired 
 p value 
 
Pre RT                                               
Mid RT          
End of 
RT 
3 months 
post RT
  
 
     6 
  5 
     3 
 
     6 
 
 
 
0.001 
 
Pre RT – Mid RT                                                            
 
Pre RT – End of 
RT                                  
 
Pre RT – 3 
month follow up 
 
0.005
 
             0.001 
 
 
             0.038 
Table 2 b :  Olfactory threshold scores ( Left side ) during radiotherapy –                
Test of significance 
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Patients were subcategorized into three groups viz, neoadjuvant chemotherapy 
followed by radiotherapy group, surgery and adjuvant radiation therapy group and 
radiation alone group. Subsequently the olfactory threshold of patients who underwent 
neoadjuvant chemotherapy followed by radiotherapy as compared with the patients 
belonging to the surgery and adjuvant radiation therapy group and radiation alone 
group was analysed. The results show delayed recovery of olfactory threshold in the 
chemoradiation subgroup.  
 
 
Fig 19 : Olfactory threshold RT+/- Surgery Vs Chemo RT  
subgroups (Right) 
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Fig 20 : Olfactory threshold RT+/- Surgery Vs Chemo RT 
subgroups ( Left ) 
 
Odour identification 
In comparison to the olfactory thresholds, there seemed to be a similar descending 
trend in the odour identification over the course of RT. At 3 month post RT follow up, 
there was improvement in the score, however was not back to normal. The olfactory 
identification on both sides is described with its median value in the line diagram. 
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Fig 21 : Odour identification (Median ) of right and left sides 
The following table shows the mean and standard deviation of odour identification 
score. 
 
Odour 
identification 
 
Pre RT 
 
Mid RT  
 
End of RT 
 
3 months post 
RT 
 Mean SD Mean SD Mean SD Mean SD 
 
Right                                                                  
5.95 1.284 4.29 1.521 
 
3.06 
 
1.392 
 
4.38 
 
1.387 
 
Left 
 
5.78 
 
1.215 
 
4.00 
 
1.879 
 
2.88 
 
1.364 
 
4.67 
 
1.073 
 
Table 3 : Mean Odour Identification scores 
6
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Composite score  
The composite score at various time periods were significantly reduced. The mean and 
standard deviation of composite scores on the right and left side is represented in 
figures 22 & 23. 
 
 
Fig 22: Mean composite score on the right side 
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Fig 23: Mean composite score on the left side 
The composite scores before and after radiotherapy were analysed and it was found 
that there was a significant  deterioration in the mean scores and the difference was 
statistically significant (P<0.001). 
Composite score 
( Right ) 
Mean ± SD p value 
( overall ) 
                          Paired 
 p value 
Pre RT 
 
Mid RT  
 
End of RT 
 
3 months post RT 
5.90±0.66 
 
4.52±1.35 
 
3.44±1.32    
 
4.23±1.75 
 
 
 
<0.001 
Pre RT – Mid RT 
                                         
Pre RT – End of RT 
 
Pre RT – 3 months post RT 
< 0.001 
 
<0.001 
 
0.002 
Table 4a : Composite scores at each time interval (Right ) : Test of significance 
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We also analysed the mean at each time interval separately in comparison to the base 
line mean of composite score, and was found to be statistically significant. 
Composite score 
( Left ) 
Mean ± SD p value 
( overall ) 
                          Paired 
 p value 
Pre RT 
 
Mid RT  
 
End of RT 
 
3 months post RT 
5.79±0.68  
 
4.36±1.28 
 
3.14±1.27 
 
4.37±1.61 
 
 
 
< 0.001 
 
Pre RT – Mid RT 
                                                      
Pre RT – End of RT 
 
Pre RT - 3 months post RT 
 
< 0.001 
< 0.001 
 
0.014 
 
Table 4b : Composite scores at each time interval ( Left ) : Test of significance 
 
The distribution of olfactory dysfunction based on olfactory scores at the end of 
radiotherapy on right and left sides were calculated .  
 Right ( n= 18 ) Left ( n =17 ) Total( n=35 ) 
Normosmia              > 6         1 ( 5.55% )          0 ( 0.00% ) 1 ( 2.85% ) 
Mild hyposmia        5 -6          2 ( 11.11% )         1 ( 5.88% ) 3 ( 8.57% ) 
Moderate hyposmia 4 - 5         7 ( 38.90% )         5 ( 29.41% ) 12 ( 34.28%) 
Severe hyposmia     2 - 4         6 (33.33% )          9 ( 52.94% ) 15 (42.85% ) 
Anosmia                  < 2         2 (11.11% )          2 ( 11.76% ) 4 (11.42% ) 
 
Table 5 : Severity of olfactory dysfunction at the end of radiotherapy 
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Table 6 shows the distribution of severity of olfactory dysfunction  based on olfactory 
scores at 3 months post radiotherapy on right and left sides. 
 Right ( n=13 ) Left ( n= 12 ) Total( n= 25 ) 
Normosmia                 > 6        4 ( 30.76% )       2 (16.66% ) 6 (24% ) 
Mild hyposmia          5 -6         3 ( 23.07% )        5 ( 41.66% ) 8( 32% ) 
Moderate hyposmia  4 - 5        2 ( 15.38% )        1 (8.33% ) 3 (12% ) 
Severe hyposmia       2 - 4        2 ( 15.38% )        4 (33.33% ) 6 (24% ) 
Anosmia                    < 2        2 ( 15.38% )        0 ( 0.00% ) 2(8% ) 
 
Table 6 : Severity of olfactory dysfunction 3 months post radiotherapy 
 
Saccharin perception  time –  
The nasal function in terms of mucociliary clearance was evaluated with the saccharin 
perception test. At the beginning of RT, only 12 ( 57.14% ) patients had a normal 
saccharin perception time which became increasing prolonged towards the mid RT 
and end of RT where 52.38 % and 55.55% of the patient’s mucociliary function was 
clearly deranged, respectively. 
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   0 – 20 min 21 – 30 min  > 30 min 
Pre RT ( n= 21 )  12 ( 57.14 % ) 3 ( 14.28 % ) 6 ( 28.57% ) 
Mid RT ( n = 21 )  6 (28.57 % ) 4 ( 19.04 % ) 11 ( 52. 38 % ) 
End of RT ( n = 18 )  5 ( 27.77 % ) 3 ( 16.66 % ) 10 ( 55.55 % ) 
3 months post RT  
( n= 13 ) 
 8 (61.53 % ) 1 ( 7.69 % ) 4 ( 30.76% ) 
 
Table 7: Number of patients with mucociliary dysfunction at different time 
points 
 
 
 
Fig 24 : Percentage of cases with mucociliary dysfunction 
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Since about one third of the patients already had impaired mucociliary clearance 
before treatment, patients with normal saccharin perception time at the beginning of 
the study were analysed separately. There were 12 patients with normal mucociliary 
clearance prior to treatment. Table 8  shows the results in these patients.  58.32% 
patients developed prolonged mucociliary clearance time at mid RT and at end of RT 
70% patients had prolonged clearance time with 60 % showing significantly 
prolonged mucocilicary clearance time ( > 30 min ). At 3 months follow up, 62.5% 
patients continued to have prolonged mucociliary clearance time.  
 
   0 – 20 min 21 – 30 min  > 30 min 
Mid RT                  ( n= 12) 5 ( 41.66% ) 2 (16.66% ) 5( 41.66 %) 
End of RT             ( n = 10 ) 3 (30% ) 1 (10% ) 6 (60 % ) 
3 months post RT ( n= 8 ) 3 ( 37.5% ) 1 ( 12.5% ) 4 ( 50% ) 
 
Table 8: Change in mucociliary clearance in patients with normal pre RT 
mucociliary clearance time (n = 12) 
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Fig 25 : Percentage distribution of patients with initial normal mucocilicary 
clearance at various time points in RT 
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AHSP questionnaire 
The quality of life in terms of appetite, hunger, taste and smell perception was studied 
at all 4 time periods and results analysed.  
Domain       Pre RT      Mid RT      End of RT 3 months post 
RT 
     Mean ± SD     Mean ± SD     Mean ± SD     Mean ± SD 
Appetite  
( 6 – 30 ) 20.35 ± 3.602 
 
17.43 ± 4.069 
 
 
17.56 ± 3.518 
 
 
17.85 ± 3.648 
 
Present smell 
perception  
( 3 – 15 ) 
 
9.05 ± 2.089 
 
9.05 ± 3.339 8.17 ±  2.875 7.62 ± 1.981 
Present smell 
perception as 
compared to 
past 
( 3 – 15 ) 
8.10 ± 2.315 8.05 ± 2.479 8.50 ± 2.036 8.38 ± 1.557 
Taste  
( 8 – 40 ) 
24.60 ± 4.957   20.76 ± 3.590 22.11 ±  3.104 23.31± 3.772 
Hunger 
( 9 – 25 ) 
33.50 ± 4.617 29.05 ± 7.201 27.28 ± 6.461 33.77 ± 6.623 
 
Total QOL score 
95.50 ± 10.407 88.00 ± 13.462 83.50 ± 9.488 
 
90.00 ± 10.883 
 
Table 9 : Mean of each domain in the AHSP QOL questionnaire 
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Fig 26 : Trend of each domain in the AHSP questionnaire 
 
 
Fig 27: Mean total QOL score over various time points of RT 
Although, there is no gross variation in the smell, appetite, hunger, taste perception 
scores, when the total QOL scores were compared before and after therapy, there 
appeared to be a fall in the overall total QOL score post therapy. 
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Domain Time point P value 
Appetite  
 
Pre RT – Mid RT 
Pre RT – End of RT 
Pre RT – 3 months post RT 
0.044 
0.047 
0.087 
Present smell perception  
 
Pre RT – Mid RT 
Pre RT – End of RT 
Pre RT – 3 months post RT 
0.719 
0.319 
0.225 
Present smell perception as 
compared to past 
 
Pre RT – Mid RT 
Pre RT – End of RT 
Pre RT – 3 months post RT 
0.795 
0.320 
0.480 
Taste  
 
Pre RT – Mid RT 
Pre RT – End of RT 
Pre RT – 3 months post RT 
0.025 
0.099 
0.192 
Hunger 
 
Pre RT – Mid RT 
Pre RT – End of RT 
Pre RT – 3 months post RT 
0.049 
0.010 
0.639 
 
Total QOL score 
Pre RT – Mid RT 
Pre RT – End of RT 
Pre RT – 3 months post RT 
0.020 
0.004 
0.147 
 
Table 10: AHSP QOL score at each time interval: Test of significance 
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Patients were often unaware of the olfactory loss as evident in the threshold scores 
which directly did not significantly affect the quality of life. However, gustation and 
appetite related quality of life seemed to be significantly affected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76 
 
DISCUSSION 
Radiation therapy is an integral component in the management of head and 
neck malignancies and the radiation fields often include the olfactory cleft region. 
Such patients sometimes complain of deteriorating chemosensory function during the 
course of treatment. Olfactory impairment is most often overlooked even though it 
could expose patients to potentially life-threatening events. In order to look at this 
aspect of effect of radiotherapy on nasal functions, the present study was designed and 
conducted. 
We assessed olfaction in 33 head and neck cancer patients, planned for IMRT, 
who agreed to participate in the study. Strictly adhering to normal olfaction at 
baseline, 21 patients could be recruited in the study. At the time of analysis, 18 
patients had completed radiotherapy and 13 were followed up 3 months post 
treatment.  
The age group ranged from 16 – 75 years. Generally, the overall incidence of 
head and neck cancers is much more common in men as compared to women. In our 
study also there was a male predominance noted.  
Our study is based on the Connecticut chemosensory clinical research centre 
test (CCCRC) in patients diagnosed with primary head and neck cancers after 
irradiation. In the selection of cases, patients with head and neck cancer in whom the 
irradiation field included the olfactory cleft were only studied. Standardized 
irradiation techniques and head and neck cancer treatment guidelines according to 
institutional protocols were followed.  
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All patients in the study were treated with intensity modulated radiotherapy. 
After determining the exact site, dose and tumour volume to be irradiated, 200 cGy (2 
Gy) of irradiation per day was given for 5 days a week in all the cases over a period of 
6 – 7 weeks in 33 to 35 fractions. Total dose ranged from 60 – 70 Gy ( Mean total 
dose – 65.75 Gy ). The mean olfactory region dose volume varied from 0.00 – 2.36 
cm3 ( Mean – 1.47 cm3). 
Although, the CCCRC test is a fairly simple procedure, some of the odorants in 
the study could be perceived but not identified by some patients. Our study shows a 
gradual decline in both olfactory threshold and odour identification in individuals with 
normal olfaction following 2 weeks of radiotherapy which progressed until the end of 
radiotherapy ( p  <0.001). This could be a conductive defect due to oedema of the 
nasal mucosa and also partly sensorineural due to effect of radiation on the olfactory 
receptors and nerve fibres. In patients in whom treatment was complete, when 
assessed during their 3 month follow up, there was recovery of olfaction to normal in 
a few while olfactory loss still persisted in others. Olfactory thresholds alone were 
analysed in the subgroups that underwent chemoradiation and surgery with adjuvant 
radiotherapy or radiation alone groups. Similar results were obtained, however 
patients undergoing chemoradiation reported a delayed recovery or the olfaction did 
not return to normal. This was in contradiction to the findings in a study by 
Yakirevitch et al where he reported cisplatin has no deleterious effects on olfactory 
function (27).  
In a study by Jalali et al where 54 patients with head and neck cancer treated by 
radiotherapy were assessed, the mean olfactory threshold scores were found to 
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deteriorate significantly at various time points after radiotherapy (11.7 before 
radiotherapy versus 4.0 at   3 months  general linear model, ( P<0.0001). Olfactory 
threshold was significantly decreased 2–6 weeks after initiation of therapy. However, 
this study showed no recovery of olfaction upto 6 months follow up (31).  
In a similar study by Ophir et al , on patients with nasopharyngeal carcinoma or 
pituitary adenoma treated by radiotherapy, the olfactory function significantly reduced 
during the course of treatment. However, most patients showed varying degrees of 
recovery 3 -6 months after treatment (35).  This is in agreement with our study where 
a significant reduction was noted at mid RT assessment. Even though there was an 
improvement in olfaction at the 3 month post RT evaluation, it continued to be 
significantly reduced compared to the pre RT baseline. 
Ho et al measured olfactory threshold, odour identification, and odour 
discrimination in 48 patients using the ‘Sniffin– Sticks’ test at five time points  from 
beginning of RT till 1 year follow up after treatment for nasopharyngeal carcinoma. 
Contrary to our findings, a mostly negative result was found in this prospective study. 
Only 12 months after radiotherapy there was a significant deterioration in olfactory 
thresholds. However, olfactory discrimination and identification did not show any 
significant change (32).  
Hölscher et al studied olfactory function in 44 patients, 25 of whom were 
followed for 12 months. Based on the dose of radiation to the olfactory epithelium, 
patients were divided into two groups: median 62.2 Gy (OLF group) and median 5.9 
Gy (non-OLF group). This study showed a significant impairment of odour 
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discrimination or odour identification in the OLF group with no significant changes in 
olfactory thresholds. The observed changes were attributed to the effects of 
radiotherapy on the olfactory bulb/orbitofrontal cortex. The authors postulated that the 
olfactory epithelium is relatively resistant against the effects of radiation (33).  
 In a study by Veysellar et al, the long-term side effects of radiotherapy on the 
olfactory bulb volumes and olfactory function in nasopharyngeal cancer patients were 
evaluated. The olfactory bulb volumes on MRI scan and olfactory threshold of 
nasopharyngeal cancer patients was significantly diminished as compared to healthy 
controls. This was attributed to the direct radiation induced damage to the olfactory 
mucosa or the effect of radiotherapy to primarily the olfactory bulb and other 
olfactory centers (34).  
In a study by Brammerson et al, the olfactory identification was assessed using 
the Scandinavian Odor Identification Test (SOIT ) which showed that the 
identification test given before treatment yielded a mean score of 12.4 in the high-dose 
group and 12.5 in the low-dose group for which corresponding scores after treatment 
were 10.2 and 12.4. Before treatment there was no significant difference between 
groups, but after treatment high dose group showed a significant reduction (p < 0.05) 
(30). 
According to the CCCRC composite scores in the present study, 3 months after  
radiotherapy, patient distribution based on severity of olfactory symptoms was: 
normosmia 6 ( 24% ), mild hyposmia 8 (32% ), moderate hyposmia 3( 12 % ), severe 
hyposmia 6 ( 24% ) and anosmia 2 (8 % ). 
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Veyseller et al reported, composite scores of 11 (45.8%) patients classified as 
normal, 7 (29.2%) as mildly hyposmic, 3 (12.5%) as moderately hyposmic, and 3 
(12.5%) as severely hyposmic in tests conducted 12 months after treatment.  
Wang et al, reported the significant decrease in  UPSIT scores with a mean of 
30.6 before IMRT and a mean of 28 after IMRT. However, 75.6% of patients retained 
normal olfactory function after IMRT which indicated that most nasopharyngeal 
carcinoma patients were not affected by IMRT (20) . 
Based on the site of lesion on the olfactory pathway, Snow et al has classified 
olfactory disorders in to 3 types, transport, sensory, and neural disorders. In transport 
olfactory disorders, there is reduced transmission of odorant particles to the 
neuroepithelium, whereas sensory olfactory disorders involve lesions of the 
neuroepithelium itself. In our study patients, the mechanism of olfactory dysfunction 
may include both transport and sensory olfactory losses. Radiotherapy induced 
mucosal changes like oedema and mucositis can lead to obstruction of access of 
odorant particles to the olfactory area resulting in a conductive type hyposmia even 
though often the patient doesn’t feel the nasal obstruction. In addition, irradiation can 
damage the olfactory epithelial Bowman’s glands which dissolve odorants and present 
them to bipolar receptor cells. Any significant change in the microenvironment around 
the olfactory receptor neurons is detrimental to the appreciation of smell (12). 
  The alteration in cell cycle and arrest of mitosis in the basal cell layer of 
olfactory epithelium leading to a decreased turnover of olfactory neuroepithelium is 
postulated to be yet another mechanism by which irradiation affects olfaction. The 
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regenerative capability of olfactory neuroepithelium could be the reason for recovery 
of olfactory function few months following radiotherapy as noticed in our study too. 
According to Jalali et al, variability in the total irradiation dose to the olfactory 
region can have different effects. Low radiation doses cause olfactory threshold 
change due to sensory perception. Irradiation in higher doses is hypothesised to cause 
nerve damage in addition to the mucosal damage. This could account for the 
contradictory results of different studies (31).  
Another important aspect of nasal function is the nasal mucociliary clearance. 
The process by which the particles inhaled in the nasal mucosa are pushed towards the 
nasopharynx through the ciliary movement is called mucociliary clearance (MCC). 
Usually, the mucosal ciliary activity of the nasal cavity sweeps the mucosal blanket 
posteriorly at a rate of 6 – 7 mm/ min till the nasopharynx where it is swallowed. This 
is dependent on the physical properties of the mucus and proper function of the cilia. 
Several studies have been reported to show effects of age, gender, inflammation, 
temperature changes and drugs on the mucociliary clearance time. Many patients 
undergoing radiation therapy for head and neck cancers complain of nasal congestion, 
facial pain and foul smell during treatment.  This was attributed to the prolonged 
mucociliary clearance time and inadequate drainage of secretions. Similar symptoms 
were reported by Kiliç et al and Stringer et al (41,42).   
Damage to the respiratory mucosa and the cilia due to direct effects of 
irradiation have been reported in animal and human studies following physiological 
changes such as vacuolation of the ciliary cells, goblet cell secretions, nuclear 
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pyknosis, decreased ciliary cells and sloughing. Even though there are numerous 
studies on mucociliary clearance there is paucity of literature on the effect of radiation 
therapy on this phenomenon. The study aimed to demonstrate how the nasal 
mucociliary transport times are affected in the patients receiving radiotherapy for head 
and neck tumours. We assessed the mucociliary clearance time by the saccharin test. 
In our study, out of the 21 patients, only 12 (57.14%) patients had normal mucociliary 
clearance time before initiation of radiotherapy.  This could be because majority of the 
study patients had carcinoma of the nasopharynx  (61.9% ) having a mass  which 
contributed to the obstruction of mucus clearance. The decrease in mucociliary 
clearance rate could also be attributed to the toxic effect of the chemotherapy regimen 
on cilia movement and/or mucus structure since 71 % of the participants had 
undergone chemoradiation. Another contributing factor impeding the mucociliary 
clearance could be an in situ nasogastric tube in many of these patients.  
There was a prolonged saccharin perception time at the end of radiation 
(21.44±1.2400 ) as compared to the start of radiation (Mean + SD 14.80±8.637 ). 
There were wide variations in the results as several patients were unable to perceive 
saccharin at all. This could be attributed to the fact that several patients were placed 
on nasogastric tube feeds which further occluded the nasal cavity. Analysis of results 
in the surgery and RT subgroups as well as chemoradiation subgroups also yielded 
similar results. 
A study by Gupta et al, showed significantly prolonged saccharin perception 
time in head and  neck cancer patients after radiotherapy when compared to their pre 
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irradiation values [pre RT (Mean + SD-9.45 ± 0.36 minutes) while post RT (Mean + 
SD - 30.64 ± 1.12 minutes] (24). 
Stringer at al evaluated the mucociliary function in 9 patients who had 
previously undergone radiotherapy. The irradiated patients had a negative saccharin 
test similar to our study where several patients did not perceive the saccharin 
following the initiation of radiotherapy.  
Kiliç et al, demonstrated significantly prolonged mucociliary clearance time in 
nasopharyngeal and laryngeal cancer patients who received RT which persisted  at 3 
months and 6 months follow up in the nasopharyngeal cancer patients (41).  
Radiation therapy has a negative impact on the quality of life as reported by 
many researchers. In a study of patients  undergoing chemotherapy, Epstein et al  
reported, the greatest changes in QOL were seen to be the impact upon physical, 
emotional, cognitive, and social functions.(37) He reported a reduced taste (ageusia) 
or altered taste (dysgeusia), which may have a signiﬁcant impact on QOL in patients 
undergoing radiation and/or chemotherapy. Decreased food intake could be due to  
decreased appetite (28)induced by nausea and altered taste or smell,  oral ulcers and 
oropharyngeal mucositis, hyposalivation, and xerostomia and decreased interest in 
food associated with depression.  
Braam et al reported a prospective study of the QOL combined with parotid 
salivary outflow of 44 patients with head-and-neck malignancies treated with RT. 
They assessed xerostomia using the EORTC –H&N35 questionnaire which revealed 
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deterioration of most of the QOL items after completion of radiotherapy compared 
with baseline, with improvement during 5 years follow-up, even after 12 month (43) .  
Leyrer et al  performed a dose-volume histogram analysis in 20 patients with 
gliomas. The patients completed a questionnaire relating to taste and smell 
disturbances at baseline and at Weeks 3 and 6. Ten of 20 patients reported 
experiencing some degree of smell disturbance (36).  
Kamel et al, conducted serial follow up studies on mucociliary clearance of 
patients who received RT over a period of 2 – 4 years post therapy. They concluded 
that the MCC deteriorates for up to 6 months and then stabilizes and persists due to 
damage to  ciliary motility. Serial nasal endoscopies revealed  a decrease in the 
amount of discharge, resulting in thick mucous with adhesions and choanal stenosis 
causing accumulation of the crusts (44). 
We used the Appetite, hunger, taste and smell perception ( AHSP ) 
questionnaire designed by Dr De Jong. It consisted of 5 domains with a total of 29 
questions which made inquiries in to present status of the patients’ appetite, smell, 
frequency on meals, alterations in taste as well as comparisons made to previous 
disease free period. Each domain was analysed separately (40).  
Patients at each visit were also enquired about their general health. Patients 
complained of generalised weakness, oral ulcers and decreased taste perception but 
were unaware of deterioration in olfactory function. Mean scores in each domain were 
comparable to the baseline and did not show drastic differences. Overall total QOL 
score at the end of RT was reduced (83.50 ± 9.488 ) as compared to the total score 
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prior to radiotherapy (95.50 ± 10.407 ). However, individual components such as 
appetite and hunger were also significantly reduced even though olfaction  did not 
show a significant reduction. 
 
Limitations  
Most patients come from different parts of India with different cultures and 
tradition.  There is no single globally acceptable olfaction assessment tool for all these 
patients. Patients were sometimes unfamiliar with the components used for odour 
identification and the test had to be repeated. Some patients were unwilling for 
repeated follow up because of their physical and emotional condition while 
undergoing concurrent chemoradiation.  
Factors such as nasogastric tubes, nasal packing were confounding. Hence, 
prolonged effects of mucociliary clearance time could not be effectively assessed. 
Further more, the less number of studies in this area of interest along with different 
tests used in the studies did not favour comparison of data.   
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CONCLUSION 
 
Radiotherapy has a significant effect on nasal functions of olfaction and 
mucociliary clearance. Both olfactory threshold and identification showed significant 
reduction during the course of radiotherapy with partial recovery at 3 months follow 
up. In patients who underwent chemoradiation recovery of olfactory function was 
comparatively less.  Mucociliary dysfunction persisted even after 3 months following 
radiation therapy. The patients did not notice olfactory dysfunction subjectively. 
Impairment of quality of life can be attributed as an indirect  impact of olfactory loss.  
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                                        PATIENT INFORMATION SHEET 
 
You are being requested to participate in a study . In this study we will test your olfaction 
(ability to smell ) before and after radiotherapy. We will assess the ability to smell prior to 
initiation of radiotherapy. Subsequently, your quality of life and nasal function test will also 
be done. 
Olfaction testing is done using Butanol test. In this test you will be given a solution at 
different concentrations and you will be asked at which concentration you can identify the 
smell. You will also be asked to smell different odours and see if you can differentiate 
between the odours and identify them separately. 
Quality of life will be assessed using a questionnaire containing a series of 29 questions for 
which you will have to choose your answers from 5 different options. 
Nasal function will be tested by a saccharine test where in a small particle will be placed in 
the nasal vestibule and the time taken for you to identify it presence by taste will be noted. 
What are Butanol test, odour identification and odour discrimination? 
Butanol is butyl alcohol (chemical ) which is given at different dilutions and you will be 
asked to smell the different concentrations and tell us at which concentration you can identify 
the smell. The test is repeated independently in each of the nostrils. In odour identification 
and discrimination you are asked to smell different odours we use on a daily basis such as 
coffee, cinnamon etc. and you are expected to identify the odour and differentiate it. 
 
Does butanol test have any side effects.  
There are no side effects for these tests. This will only assess the extent of your ability to 
smell. 
 
How and where will the nasal tests be done? 
Your nasal examination will be done in the ENT OPD treatment room no. – 27  using a 
butanol ( chemical ) solution at different concentration  and nasal function by the saccharine 
test. 
 
Will you be charged for the nasal examination 
You will not be charged for the nasal examination. 
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Can you withdraw from this study after it starts? 
Your participation in the study is highly valuable and voluntary. You are free to decide to 
withdraw from the study at any time. If you do so, this will not affect your usual treatment in 
the hospital. 
 
Will you have to pay for the olfactory test and the nasal function test? 
You need not pay for the smell test and nasal function test. Any other treatment that you  
usually take will continue as usual. 
 
Will the questionnaire be easy to answer? 
The questionnaire will be easy and answers will be of multiple choice. A doctor will be with 
you while answering the questionnaire. Any problem in understanding the questions can be 
clarified with him / her. 
 
Will the answers of the questionnaire be kept confidential? 
The answers of this questionnaire will not be revealed or published. The questionnaire is only 
to quantify the problem pre and post radiotherapy. The results will be reviewed by only 
people associated with the study 
 
Will  your personal details be kept confidential? 
The results of this study will be publishes in a medical journal but you will not be identified 
by name in any publication or presentation of results.  
 
 
Contact : 
Dr. Preethi Rose Gurushekar 
PG Registrar 
ENT 
Ph no. – 8098233772  
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Informed Consent form  
 
Study Title:  Study of smell after radiotherapy in head and neck cancer patients 
 
Study Number: ____________ 
 
Subject’s Initials: __________________  
 
Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ 
for the above study and have had the opportunity to ask questions. [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [  ] 
 
(iii)  I understand that the Ethics Committee and the regulatory authorities will not need 
my permission to look at my health records both in respect of the current study and 
any further research that may be conducted in relation to it, even if I withdraw from 
the trial. I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [  ] 
 
(v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/_____ 
 
Signatory’s Name: _________________________________         Signature:  
 
Or 
 
 
 
 
 
 
 
 
Representative: _________________ 
 
Date: _____/_____/______ 
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Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
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PROFORMA FOR DATA COLLECTION 
Name: 
Age : 
M/F: 
Hospital number: 
Phone number: 
Clinical history: 
 
 
ENT history : 
 
 
Diagnosis: 
 
Treatment plan:  
                                                                                              
CCCRC Test: 
Olfactory threshold - 
 
 
                     Right nostril                Left nostril 
     Pre 
     RT 
Mid      
RT 
End of 
RT 
3 months Pre 
RT 
Mid      
RT 
End of 
RT 
3 months 
     0     0     0     0     0      0      0      0 
     1     1     1     1     1      1      1      1 
     2     2     2     2     2      2      2      2 
     3     3     3     3     3      3      3      3 
     4     4     4     4     4      4      4      4 
    5     5     5     5     5      5      5      5 
    6     6     6     6     6      6      6      6 
    7     7     7     7     7      7      7      7 
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Odour identification test –  
Odorant 
 
 
 
Right nostril 
 
Left nostril 
 
Pre RT Mid 
RT 
End of 
RT 
3 
months 
post 
RT 
Pre RT Mid 
RT 
End of 
RT 
3 
months 
post 
RT 
Cinnamon         
Asafoetida         
Coffee         
Tea         
Pepper         
Clove oil         
Baby powder         
Total correct         
Eucalyptus 
( Trigeminal ) 
        
Key          √ 
Correct  
NS – No 
sensation 
DK – Don’t 
know 
Misidentification 
to be specified 
 
Score -  
 Pre RT Mid RT End of RT 3 months post RT 
    R    L    R    L    R   L    R    L 
Olfactory 
threshold 
        
Odour 
identification 
        
Composite  
Score 
        
    
 Pre RT Mid RT    End of RT    3 months post 
RT 
Quality of life     
Mucociliary 
Clearance time 
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Appetite, Hunger and Sensory Perception (AHSP) questionnaire 
TASTE 
In former days I enjoyed food: 
[ ] 1 much more than nowadays 
[ ] 2 more than nowadays 
[ ] 3 the same as nowadays 
[ ] 4 less than nowadays 
[ ] 5 much less than nowadays 
It seems that all foods have the same taste 
[ ] 1 totally agree 
[ ] 2 agree 
[ ] 3 no opinion 
[ ] 4 disagree 
[ ] 5 totally disagree 
It seems that the taste of food 
[ ] 1 seriously declined 
[ ] 2 declined 
[ ] 3 stayed the same 
[ ] 4 improved 
[ ] 5 seriously improved 
 I still eat with relish 
[ ] 5 totally agree 
[ ] 4 agree 
[ ] 3 no opinion 
[ ] 2 disagree 
[ ] 1 totally disagree 
In former days, food was 
[ ] 1 much more enjoyable than nowadays 
[ ] 2 more enjoyable than nowadays 
[ ] 3 as enjoyable as nowadays 
 viii 
 
[ ] 4 less enjoyable than nowadays 
[ ] 5 much less enjoyable than nowadays 
In general, I find food taste 
[ ] 5 very good 
[ ] 4 good 
[ ] 3 fair 
[ ] 2 bad 
[ ] 1 very bad 
In former days I enjoyed eating 
[ ] 1 much better than nowadays 
[ ] 2 better than nowadays 
[ ] 3 the same as nowadays 
[ ] 4 worse than nowadays 
[ ] 5 much worse than nowadays 
Nowadays the food is rather tasteless 
[ ] 1 totally agree 
[ ] 2 agree 
[ ] 3 no opinion 
[ ] 4 disagree 
[ ] 5 totally disagree 
APPETITE 
Nowadays my appetite is generally 
[ ] 5 very good 
[ ] 4 good 
[ ] 3 fair 
[ ] 2 bad 
[ ] 1 very bad 
Nowadays I donot feel too much like eating 
[ ] 1 totally agree 
[ ] 2 agree 
 ix 
 
[ ] 3 no opinion 
[ ] 4 disagree 
[ ] 5 totally disagree 
In former days my appetite was 
[ ] 1 much better than nowadays 
[ ] 2 better than nowadays 
[ ] 3 the same as nowadays 
[ ] 4 worse than nowadays 
[ ] 5 much worse than nowadays 
It seems that my appetite 
[ ] 1 seriously declined 
[ ] 2 declined 
[ ] 3 stayed the same 
[ ] 4 improved 
[ ] 5 seriously improved 
Everyday I feel like eating 
[ ] 5 totally agree 
[ ] 4 agree 
[ ] 3 no opinion 
[ ] 2 disagree 
[ ] 1 totally disagree 
I still have a hearty appetite 
[ ] 5 totally agree 
[ ] 4 agree 
[ ] 3 no opinion 
[ ] 2 disagree 
[ ] 1 totally disagree 
SMELL BEFORE 
In former days my sense of smell was 
[ ] 1 much finer than nowadays 
 x 
 
[ ] 2 finer than nowadays 
[ ] 3 as fine as nowadays 
[ ] 4 less fine than nowadays 
[ ] 5 much less fine than nowadays 
In former days, most of foods smelled 
 [ ] 1 much better than nowadays 
[ ] 2 better than nowadays 
[ ] 3 the same as nowadays 
[ ] 4 worse than nowadays 
[ ] 5 much worse than nowadays 
It seems that my sense of smell was better in former days than now 
[ ] 1 totally agree 
[ ] 2 agree 
[ ] 3 no opinion 
[ ] 4 disagree 
[ ] 5 totally disagree 
SMELL NOWADAYS 
I smell 
[ ] 1 very well 
[ ] 2 well 
[ ] 3 fairly 
[ ] 4 badly 
[ ] 5 very badly 
It seems that everything smells the same 
[ ] 1 totally agree 
[ ] 2 agree 
[ ] 3 no opinion 
[ ] 4 disagree 
[ ] 5 totally disagree 
Nowadays I am not able to identify a lot of odours 
 xi 
 
[ ] 1 totally agree 
[ ] 2 agree 
[ ] 3 no opinion 
[ ] 4 disagree 
[ ] 5 totally disagree 
HUNGER FEELINGS 
How often do you feel like eating your breakfast? 
[ ] 5 daily 
[ ] 4 often 
[ ] 3 sometimes 
[ ] 2 seldom 
[ ] 1 never 
How often do you feel like eating your lunch? 
[ ] 5 daily 
[ ] 4 often 
[ ] 3 sometimes 
[ ] 2 seldom 
[ ] 1 never 
How often do you feel like eating your dinner? 
[ ] 5 daily 
[ ] 4 often 
[ ] 3 sometimes 
[ ] 2 seldom 
[ ] 1 never 
How often do you feel like eating a snack? 
[ ] 5 daily/ several times a day 
[ ] 4 often 
[ ] 3 sometimes 
[ ] 2 seldom 
[ ] 1 never 
 xii 
 
How often do you feel like eating something sweet? 
[ ] 5 daily/ several times a day 
[ ] 4 often 
[ ] 3 sometimes 
[ ] 2 seldom 
[ ] 1 never 
How often do you feel like eating something salty? 
[ ] 5 daily/ several times a day 
[ ] 4 often 
[ ] 3 sometimes 
[ ] 2 seldom 
[ ] 1 never 
How often do you have to force yourself to eat something? 
[ ] 1 always 
[ ] 2 often 
[ ] 3 sometimes 
[ ] 4 seldom 
[ ] 5 never 
How often are you looking forward to the next meal? 
[ ] 5 always 
[ ] 4 often 
[ ] 3 sometimes 
[ ] 2 seldom 
[ ] 1 never 
If you have been snacking, do you still feel like eating your next meal? 
[ ] 5 always 
[ ] 4 often 
[ ] 3 sometimes 
[ ] 2 seldom 
[ ] 1 never
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ID NAME HOSP AGE GENDER COMD DIAG STAGE TNM RX SX HISTOLOGY R R1 R2 R3 L 
1 
Mihir Chandra 
Debnath 497887g 36 1 2 1 4 T2N3M0 3   
Undifferentiated nasophyngeal 
ca 6 5 4 6  
2 Sudhamoy Misra 640434g 38 1 3 3    1 
Left inferior partial 
maxillectomy Clear cell mucoepidermoid ca 6 6 2 6 6 
3 
Mahendra Singh 
Prasad 672169g 57 1 3 2 4 T4N2M0 3   Poorly differentiated ca 6 6 4   6 
4 
Kharka Bahadur 
Limboo 698685g 52 1 3 1 4 T1N3bM0 3   Poorly differentiated ca 6 6 6 6 6 
5 
Suvankar 
Rakshit 648128g 16 1 3 4    1 
Endoscopic excision 
right nasal mass 
Haemangiopericytoma right 
nasal cavity 6 6 3 6 6 
6 Bavish Karmakar 699256g 17 1 3 1 3 T3N1M0 3   
Undifferentiated 
nasopharyngeal ca 6 6 6 6 6 
7 
Rajendra 
Bahadur Chettry 706189g 69 1 3 2 3 T3N0M0 2   Poorly differentiated ca 6 6 4 4 6 
8 
Abdullah 
Mamoon 732841g 59 1 1 1 3 T3N0M0 3   Poorly differentiated ca 5 4     5 
9 Lalzingtluanga 720263g 67 1 1 2 2 T2N0M0 2   Moderately differentiated SCC 6 6 1 6 6 
10 Sarika Sangdo 671586g 31 2 3 1 4 T3N3M0 3   Poorly differentiated ca 6 6 6 6 6 
11 
Mithun Kumar 
Kundu 757521g 21 1 3 1 4 T4aN2M0 3   Poorly differentiated ca 6 6 6   6 
12 
Matta Nagendra 
Prasad 766658g 39 1 3 1 4 T2N3M0 3   Poorly differentiated ca 6 4 3 4 6 
13 
Mst Salina 
Khatun 770194g 41 2 3 1    3   Poorly differentiated ca 6 4 3 3 5 
14 Dileep Kumar 767699g 22 1 3 1 4 T1N2M0 3   
Undifferentiated 
nasopharyngeal ca 6 5 6 0 6 
15 Babu 766737g 50 1 3 1 3 T1N1M0 3   
Undifferentiated 
nasophayngeal carcinoma 6 1 1 0 6 
16 Golak Modal 790529g 49 1 3 1 4 T2N3M0 3   Metastatic ca 6 5 0   6 
17 Sunitha Mishra 783924g 28 2 3 4    1 
Endoscopic excision 
of tumour 
Poorly differentiated ca with 
neuroendocrine differentiation 6 6 5   6 
18 
Shyam Sundar 
Roy 303890c 65 1 3 3 1 T1N0M0 1 
Right inferior partial 
maxillectomy + Right 
SND Squamous cell ca 6 5 3 0 6 
19 Munna 878233g 24 2 3 1 4 T4N0M0 3   
Undifferentiated 
nasopharyngeal ca 6 6 6   6 
20 Jayanthi 878817g 48 2 2 1 4 T2N2M0 3   
Poorly differentiated squamous 
cell ca 6 0      
21 Rajat 910298g 66 1 3 2 4 T4N0M0 3   
Well differentiated squamous 
cell ca 5 2      
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L1 L2 L3 R4 R5 R6 R7 L4 L5 L6 L7 R8 R9 R10 R11 L8 L9 L10 L11 SP SP1 SP2 SP3 APPTPRE PSPPRE 
   7 5 5 7     6.5 5.0 4.5 6.5     8 30     19 7 
4 2 6 7 6 2 6 6 5 2 7 6.5 6.0 2.0 6.0 6.0 4.5 3.5 6.5 30 30 30 5 19 9 
6 2   6 5 4   7 6 3   6.0 5.0 4.0   6.5 6.0 2.5   25       15 11 
6 6 6 6 3 0 3 4 2 2 4 6.0 4.5 3.0 4.5 5.0 4.0 4.0 5.0     15 1 26 11 
5 3 6 7 5 4 4 7 6 1 5 6.5 5.5 3.5 5.0 6.5 5.5 2.0 5.5     15 13 25 10 
5 5 6 7 5 4 4 7 6 4 4 6.5 5.5 5.0 5.0 6.5 5.5 4.5 5.0 10 14   9 23 9 
6 3 4 4 4 4 3 4 3 1 4 5.0 5.0 4.0 3.5 5.0 4.5 2.0 4.0 20   25 30 16 10 
4     5 1     4 1     5.0 2.5     4.5 2.5     30 30 .   22 10 
6 1 6 5 3 2 6 4 1 0 5 5.5 4.5 1.5 6.0 5.0 3.5 0.5 5.5 15 40 50   12 6 
6 4 6 7 2 2 6 6 2 3 5 6.5 4.0 4.0 6.0 6.0 4.0 3.5 5.5 6 14 15 15 24 8 
6 6   5 4 2   6 5 3   5.5 5.0 4.0   6.0 5.5 4.5   17 21 13   20 7 
1 0 0 7 4 4 4 5 3 4 4 6.0 4.0 3.5 4.0 5.5 2.0 2.0 2.0 13 45   15 17 6 
4 3 3 6 6 4 4 5 5 5 3 6.0 5.0 3.5 3.5 5.0 4.5 4.0 3.0   10 20 20 23 14 
4 6 0 6 6 3 3 5 2 4 4 6.0 5.5 4.5 1.5 5.5 3.0 5.0 2.0 20       22 6 
2 3 0 5 2 2 4 7 3 4 5 5.5 1.5 1.5 2.0 6.5 2.5 3.5 2.5 3 1 10   24 11 
4 0   2 5 1   6 4 2   4.0 5.0 0.5   6.0 4.0 1.0           18 9 
6 4   7 7 4   7 6 4   6.5 6.5 4.5   6.5 6.0 4.0           20 10 
6 3 6 7 5 3 3 7 6 4 6 6.5 5.0 3.0 1.5   6.0 3.5 6.0   5   15     
4 4   7 5 5   7 6 3   6.5 5.5 5.5   6.5 5.0 3.5   7 15     23 7 
     6 3           6.0 1.5           8       20 10 
     6 4           5.5 3.0           10       19 10 
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PSPPP
RE 
PTPP
RE 
HUN
G 
TOTALP
RE 
APPTM
ID 
PSPMI
D 
PSPPM
ID 
PTPMI
D 
HUN
G1 
TOTALM
ID 
APPTPO
ST 
PSPPO
ST 
PSPPPO
ST 
PTPPO
ST 
HUN
G2 
TOTALP
OS 
APPT3M
ON 
10 27 30 93 14 6 7 17 22 66 11 4 7 15 22 59 16 
9 31 37 99 6 4 7 13 15 45 15 6 10 25 37 93 11 
11 21 36 96 20 10 10 25 40 105 19 8 13 28 13 81   
9 32 40 118 16 3 9 22 38 88 17 10 7 23 29 86 21 
7 27 38 107 22 10 8 25 34 99 18 5 7 23 35 88 18 
8 29 35 104 17 12 7 21 25 82 19 10 8 20 23 80 15 
11 36 37 100 19 13 7 24 26 89 24 12 11 25 26 98 23 
8 28 38 106 18 12 7 14 30 81               
8 20 26 72 22 6 10 25 38 101 17 6 9 25 30 87 19 
6 21 38 97 16 8 9 23 32 88 12 10 10 21 30 83 20 
7 26 21 81 16 15 6 21 35 93 18 13 7 21 29 88   
9 21 35 88 14 5 11 19 28 77 15 5 12 18 23 73 19 
7 20 33 97 24 9 7 25 28 93 16 10 7 25 25 83 16 
10 22 35 95 13 9 10 18 13 63 19 5 8 20 27 79 21 
12 28 29 104 16 6 11 18 31 82 26 4 10 24 34 98 12 
4 21 31 85 22 10 4 20 28 84 18 10 7 23 16 74   
6 19 30 85 20 7 3 19 40 89 17 8 6 21 32 84   
        14 15 4 20 29 82 17 10 7 19 25 78 21 
3 20 34 87 19 10 10 25 26 90 18 11 7 22 35 93   
10 19 33 92 17 11 12 23 27 90               
7 24 34 94 21 9 10 19 25 84               
 i 
 
 
PSP3M
ONT 
PSPP3
MON 
PTP3M
ONT 
HUN
G3 
TOTAL
3MO 
DO
SE 
CYCL
ES 
meantotal
dose 
phase 1  
mea
n 
total 
dose 
phas
e 2 
MEANOLFACTORYREGI
ONDOSEcGy 
MEANOLFACTORYREGI
ONVOLUME 1 
MEANOLFACTORYREGI
ONVOLUME - 2 
MEANOLFACTORYREGI
ONVOLUME 2 
8 7 20 29 80 66 33 6718  2,820.3 42.7  
6 11 18 21 67 66 33 5,625.2 
6,69
7.1 6,735.4 102.2 101.5 
          70 35 6,848.5 
7,03
7.5 601.4 0.1 7.9 
7 7 27 33 95 66 33 6701.3  5,432.9 82.3  
9 6 28 35 96 60 30 6131.7  6,165.0 102.8  
10 7 22 41 95 66 33 6674.9  5,782.2 87.6  
12 10 29 32 106 70 35 6,254.0 
7,10
6.2 294.9 0.0 2.9 
          70 33 7097.1  2,777.0 39.7  
6 9 23 33 90 70 35 5,717.0 
7,10
1.8 373.7 0.0 2.6 
8 10 27 39 104 70 33 7132.1  5,837.1 83.4  
          63 30 6070.7  6,139.9 102.3  
7 9 21 45 101 70 33 7079.6  3,788.5 63.8  
7 7 25 25 80 66 33 6,318.8 
7,08
4.8 5,962.1  82.4 
7 8 23 30 89 70 33 7159.5  2,375.0 33.9  
8 10 23 37 90 70 35 7110.9  2,162.9 30.9  
          70 33 7158.8  3,405.3 48.7  
          66 33 6606.2  6,559.8 99.4  
4 8 17 39 84 70 35 6748.4  1,664.9 28.0  
              7013  5,690.0 95.8  
              7036.9  1,414.6 20.2  
              7106.2  162.5 2.3  
 
